MusclePharm (MSLPQ) 10-Q 14 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 13, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'MusclePharm Corp	'
Entity Central Index Key	'0001415684	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'MSLP	'
Entity Common Stock, Shares Outstanding	'	13,111,792

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash	$2,949,773	$5,411,515
Cash - restricted	'	2,500,014
Investment in debt securities	'	259,715
Accounts receivable - net	23,220,072	13,741,180
Derivative instrument	'	119,248
Inventory	24,027,143	15,772,368
Prepaid giveaways	1,434,850	1,177,539
Prepaid stock compensation	4,419,721	3,023,717
Prepaid sponsorship and endorsement fees	506,478	1,145,161
Prepaid expenses	1,832,217	1,335,218
Other assets	637,424	40,805
Total current assets	59,027,678	44,526,480
Property and equipment - net	7,303,012	2,613,584
Intangible assets - net	6,866,064	155,165
Prepaid stock compensation	6,142,750	4,718,238
Other assets	270,582	144,229
Total assets	79,610,086	52,157,696
Current liabilities:	'	'
Accounts payable	28,096,948	26,048,483
Accrued liabilities	4,894,350	2,317,901
Capital lease - short term	97,925	26,653
Customer deposits	250,413	265,652
Line of credit	8,000,000	2,500,000
Notes payable	45,600	62,502
Derivative liabilities	0	1,147,330
Total current liabilities	41,385,236	32,368,521
Capital lease - long term	135,689	54,639
Total liabilities	41,520,925	32,423,160
Commitments and Contingencies (Note 12)	'	'
Stockholders' Equity:	'	'
Common Stock, $0.001 par value; 100,000,000 shares authorized; 11,266,142 and 9,259,411 shares issued, respectively; and 10,996,221 and 9,089,490 shares outstanding, respectively	11,266	9,260
Additional paid-in capital	125,014,545	103,064,901
Treasury stock, at cost; 619,921 and 169,921 shares,	-7,481,179	-1,498,298
Accumulated other comprehensive (loss)	-32,392	-14,042
Accumulated deficit	-79,423,079	-81,827,417
Total stockholders' equity	38,089,161	19,734,536
Total Liabilities and Stockholders' Equity	79,610,086	52,157,696
Series D Convertible Preferred Stock [Member]	'	'
Stockholders' Equity:	'	'
Series D, Convertible Preferred Stock, $0.001 par value; 1,600,000 shares authorized, 1,500,000 shares issued; none and 131,500 shares outstanding, respectively	'	$132

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Sep. 30, 2014	Dec. 31, 2013
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	11,266,142	9,259,411
Common Stock, shares outstanding	10,996,221	9,089,490
Treasury Stock, shares	619,921	169,921
Series D Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	1,600,000	1,600,000
Preferred stock, shares issued	1,500,000	1,500,000
Preferred stock, shares outstanding	0	131,500

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Sales - net	$47,768,320	$25,343,968	$144,717,761	$73,385,193
Cost of sales	32,811,630	17,937,768	96,241,239	49,900,891
Gross profit	14,956,690	7,406,200	48,476,522	23,484,302
Operating Expenses	'	'	'	'
Advertising and promotion	7,749,156	4,043,064	19,996,905	9,635,642
Salaries and benefits	6,041,157	3,854,945	17,185,451	6,667,313
Selling, general, and administrative	3,651,739	1,936,610	7,881,047	5,000,831
Research and development	735,472	181,908	2,996,301	441,269
Professional fees	1,316,621	2,262,453	3,393,711	10,074,439
Total operating expenses	19,494,145	12,278,980	51,453,415	31,819,494
Operating (loss)	-4,537,455	-4,872,780	-2,976,893	-8,335,192
Other income (expense), net	'	'	'	'
Derivative expense	'	'	0	-96,913
Change in fair value of derivative liabilities	'	305,421	373,944	-5,466,542
Gain (loss) on settlement of accounts payable and debt	'	67,489	31,477	392,144
Gain (loss) on derivative instrument and debt security	'	444,059	-386,103	444,059
Accretion of note discount	'	115,429	'	115,429
Bargain purchase gain	5,264,854	'	5,264,854	'
Interest expense	-28,659	-1,302	-85,047	-782,747
Foreign currency transaction loss	-1,577	-4,152	-36,073	-9,865
Interest income	'	'	223,049	'
Other income, net	'	'	166,622	10,000
Total other income (expense), net	5,234,618	926,944	5,552,723	-5,394,435
Net income (loss) before income taxes	697,163	-3,945,836	2,575,830	-13,729,627
Provision for income taxes	-94,545	'	-171,492	'
Net income (loss) after income taxes	602,618	-3,945,836	2,404,338	-13,729,627
Other comprehensive income (loss)	'	'	'	'
Net change in foreign currency translation	-37,057	-13,027	-18,349	-6,950
Net change in debt securities	'	58,438	'	58,438
Total other comprehensive income (loss)	-37,057	45,411	-18,349	51,488
Total comprehensive income (loss)	$565,561	($3,900,425)	$2,385,989	($13,678,139)
Net income (loss) per share	'	'	'	'
Basic	$0.05	($0.47)	$0.23	($2.07)
Diluted	$0.05	($0.47)	$0.20	($2.07)
Weighted average number of shares used in per share calculations - Basic	11,032,996	8,475,084	10,652,781	6,626,125
Weighted average number of shares used in per share calculations - Diluted	12,612,896	8,475,084	12,112,017	6,626,125

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash Flows From Operating Activities:	'	'
Net income (loss)	$2,404,338	($13,729,627)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation of property & equipment	950,166	510,890
Bad debt	163,897	158,578
Amortization of prepaid stock compensation	2,688,442	5,384,654
Amortization of prepaid sponsorship fees	5,016,456	2,856,040
Amortization of intangible assets	422,102	0
Stock-based compensation	6,942,357	1,588,067
Amortization of debt issuance costs	1,136	335,433
Accretion of conversion option on debt security	-222,140	-115,429
Bargain purchase gain	-5,264,854	'
Gain on settlement of accounts payable	-31,477	-392,144
Loss on disposal of property & equipment	30,606	0
Derivative expense	0	96,913
Loss on debt security and derivative instrument	386,103	0
Change in fair value of derivative assets	'	-444,059
Change in fair value of derivative liabilities	-373,944	5,466,542
Changes in operating assets and liabilities, net of acquisition	'	'
Accounts receivable	-9,148,133	-7,767,673
Inventory	-7,424,271	-9,375,189
Prepaid giveaways	-257,311	-233,622
Prepaid sponsorship fees	-4,405,354	-3,610,512
Prepaid assets	-652,516	62,736
Other assets	-354,330	-1,445
Accounts payable	2,039,228	14,652,512
Accrued liabilities	1,552,297	-3,504,756
Other long-term liabilities	-7,811	7,554
Net Cash Used In Operating Activities	-5,545,013	-8,054,537
Cash Flows From Investing Activities:	'	'
Purchase of convertible promissory note and warrant	'	-2,000,000
Purchase of property and equipment	-3,735,411	-825,164
Change in restricted cash balance	'	9,148
Proceeds from sale of investment in debt security	215,000	'
Proceeds from disposal of property and equipment	1,814	1,694
Purchase of trademark	'	-104,725
Net Cash Used In Investing Activities	-3,518,597	-2,919,047
Cash Flows From Financing Activities:	'	'
Proceeds from line of credit	8,000,000	0
Payment on notes payable	-16,902	-4,397,107
Repurchase of common stock (treasury stock)	-1,362,881	-103,537
Proceeds from issuance of preferred stock	'	12,000,000
Proceeds from issuance of common stock and warrants	'	10,827,501
Stock issuance costs	'	-1,662,667
Net Cash Provided by Financing Activities	6,620,217	16,664,190
Effect of exchange rates on cash and cash equivalents	-18,349	-6,950
Net (decrease) increase in cash	-2,461,742	5,683,656
Cash at beginning of period	5,411,515	0
Cash at end of period	2,949,773	5,683,656
Supplemental disclosures of cash flow information:	'	'
Cash paid for interest	78,820	410,846
Cash paid for taxes	240,304	0
Supplemental disclosure of non-cash investing and financing activities:	'	'
Stock issued for future services - third parties	5,402,300	13,879,997
Stock issued for Biozone acquisition	9,478,330	'
Treasury stock received in Biozone claim	4,620,000	'
Warrants issued in conjunction with equity issuances	'	8,175,459
Stock issued to settle accounts payable and accrued expenses- third parties	'	5,916,252
Stock issued for executive and board compensation	115,358	152,412
Reclassification of derivative liability to additional paid in capital	773,386	11,688,463
Net change in debt securities	'	58,438
Capital leases	$88,861	'

The_Company_and_Basis_of_Prese

The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
The Company and Basis of Presentation	'
	Note 1: The Company and Basis of Presentation
	MusclePharm Corporation (the “Company”) is a scientifically driven, performance lifestyle Company that develops, manufactures, markets and distributes branded nutritional supplements. The Company was incorporated in Nevada in 2006, and principal executive offices are located in Denver, Colorado.
	The accompanying interim unaudited consolidated financial statements as of September 30, 2014 and 2013, and for the three and nine months then ended, have been prepared by the Company in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) for interim financial information. The amounts as of December 31, 2013 have been derived from the Company’s annual audited financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements reflect all adjustments necessary (consisting of normal recurring adjustments) to state fairly the financial position of the Company and its results of operations and cash flows as of and for the periods presented. These financial statements should be read in conjunction with the annual audited financial statements and notes thereto as of and for the year ended December 31, 2013, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed on March 31, 2014 (the “Form 10-K”).
	The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014 or any future period and the Company makes no representations related thereto.
	Reclassification
	The Company has reclassified certain prior period amounts to conform to the current period presentation. These reclassifications had no effect on the financial position, results of operations or cash flows for the periods presented.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 2: Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries MusclePharm Canada Enterprises Corp (“MusclePharm Canada”) and Biozone Laboratories, Inc. (“Biozone Labs”). MusclePharm Canada began operations in April 2012 and Biozone Labs was acquired in January 2014. All intercompany accounts and transactions have been eliminated upon consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates and assumptions that require management’s most significant, difficult, and subjective judgment include the recognition and measurement of allowance for doubtful accounts, inventory write down, derivatives, allocation of acquisition purchase price, warrant and option valuation, and sales discounts and allowances reserve among others. Actual results experienced by the Company may differ from management’s estimates.
	Risks and Uncertainties
	The Company operates in an industry that is subject to rapid change and intense competition. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory, industry adverse publicity and other risks, including the potential risk of business failure.
	Recently Adopted Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists.” This ASU provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carry forward or a tax credit carry forward exists. Under the ASU, the Company’s unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carry forward or a tax credit carry forward. This ASU applies to all entities that have unrecognized tax benefits when a net operating loss carry-forward, a similar tax loss, or a tax credit carry-forward exists at the reporting date.  The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this ASU did not have a material impact on the Company's financial statements.
	Recent Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation – Stock Compensation” (“ASC 718”), as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material effect on the Company’s unaudited consolidated financial statements or disclosures.
	In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers" (“ASU 2014-09”), which provides guidance for revenue recognition. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets and supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition- Construction-Type and Production-Type Contracts.” ASU 2014-09’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company beginning January 1, 2017 and, at that time, the Company may adopt the new standard under the full retrospective approach or the modified retrospective approach. Early adoption is not permitted. The Company is currently evaluating the method and impact the adoption of ASU 2014-09 will have on the Company’s unaudited condensed consolidated financial statements and disclosures.
	In April 2014, the FASB issued ASU 2014-08, "Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity." ASU 2014-08 changes the criteria for reporting a discontinued operation. Under the new pronouncement, a disposal of a part of an organization that has a major effect on its operations and financial results is a discontinued operation. The Company is required to adopt ASU 2014-08 prospectively for all disposals or components of its business classified as held for sale during fiscal periods beginning after December 15, 2014. The adoption of ASU 2014-08 is not expected to have a material effect on the Company’s unaudited consolidated financial statements or disclosures.
	Significant Accounting Policies:
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments purchased with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents. At September 30, 2014 and December 31, 2013, respectively, the Company had no cash equivalents.
	The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The cash balance at times may exceed federally insured limits, and at September 30, 2014 we had one bank account that exceeded the federally insured limit, and at December 31, 2013 we had two bank accounts that exceeded the federally insured limit.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable represents trade obligations from customers that are subject to normal trade collection terms. The Company’s finance department monitors the status of customer receivables and takes actions to collect past due balances as necessary. The Company periodically evaluates the collectability of its accounts receivable and considers the need to establish an allowance for doubtful accounts based upon historical collection experience and specific customer information. Accordingly, the actual amounts could vary from the recorded allowances. There is also a review of customer discounts at the period end and an accrual made for discounts earned but not yet utilized by period end.
	Management performs ongoing evaluations of the Company’s customers’ financial condition and generally does not require collateral. Some international customers are required to pay for their orders in advance of shipment. Management reviews accounts receivable quarterly and reduces the carrying amount by a valuation allowance that reflects management’s best estimate of amounts that may not be collectible. Allowances, if any, for uncollectible accounts receivable are determined based upon the aging of accounts receivable, changes in customer credit worthiness, general market and economic conditions, and historical experience. Bad debt expense recognized as a result of our valuation allowance is classified under selling, general and administrative expense in the Consolidated Statement of Operations.  If receivable amounts are ultimately deemed to be uncollectible, the Company writes off the receivable balance against the valuation allowance.
	The Company does not charge interest on past due receivables. Receivables are determined to be past due based on the payment terms of the original invoices.
	Inventory
	Inventory is valued at the lower of cost or market value. The cost of product inventory for MusclePharm and MusclePharm Canada is computed using actual cost on a First-In First-Out basis, and the cost of inventory for Biozone Labs is computed using an average cost basis. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, and estimates are made for obsolescence, excess or slow-moving inventories, non-conforming inventories, and expired inventory.
	Prepaid Giveaways
	Prepaid giveaways represent non-inventory samples, which are given away to aid in promotion of the brand and products.
	Prepaid Sponsorship and Endorsement Fees
	Prepaid sponsorship and endorsement fees represent fees paid in connection with Company sponsorships of certain events and trade shows as well as prepaid athlete endorsement fees, which are expensed over the period the fees are earned. A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts. Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions. Generally, endorsement and sponsorship payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract. Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the performance period for which the prepayment applies.
	Prepaid Stock Compensation
	Prepaid stock compensation represents amounts paid with stock for future contractual benefits to be received. The Company amortizes these contractual benefits over the life of the contracts using the straight-line method.
	Prepaid Expenses
	Prepaid expenses consist of various payments that the Company has made in advance for goods or services to be received in the future. These prepaid expenses include legal retainers, print advertising, insurance and service contracts requiring up-front payments.
	Property and Equipment
	Property and equipment are stated at cost and depreciated to their estimated residual value over their estimated useful lives. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are relieved from the accounts and the resulting gains or losses are included in the Statements of Operations. Repairs and maintenance costs are expensed as incurred. Depreciation is provided using the straight-line method for all property and equipment. We review our property and equipment for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. An impairment loss is calculated by determining the difference between the carrying values and the estimated fair values of these assets. We did not consider any of our property and equipment to be impaired during the nine months ended September 30, 2014 or 2013.
	Intangible Assets
	Definite-lived intangible assets are amortized over their related useful lives, using a straight-line basis consistent with the underlying expected future cash flows related to the specific intangible asset. Costs to renew or extend the life of intangible assets are capitalized and amortized over the remaining useful life of the asset.  Intangible assets are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of impairment exist, an estimate of undiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset's carrying value and estimated fair value. Fair value is determined through various valuation techniques, including market and income approaches as considered necessary. See Note 17 for further disclosure of intangible assets.
	Accrued Liabilities
	Accrued liabilities consist of amounts estimated by management for future liability payments that relate to the current accounting period. Management reviews these estimates periodically to determine their reasonableness and fair presentation.
	Debt
	The Company defines short term debt as any debt payment due less than one year from the date of the financial statements. Long term debt is defined as any debt payment due more than one year from the date of the financial statements. Refer to Note 8 for further disclosure of debt liabilities.
	Derivatives
	Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in equity instruments and warrants granted, and measurement of their fair value. In determining the appropriate fair value, the Company uses Black-Scholes or lattice option-valuation models. In assessing the convertible equity instruments, management determines if the convertible equity instrument is conventional convertible equity and further if the beneficial conversion feature requires separate measurement.
	Once derivative instruments are determined, they are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value is recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using a Black-Scholes or lattice option-pricing model. Once a derivative liability ceases to exist any remaining fair value is reclassified to additional paid-in capital if redeemed or through earnings if forfeited or expired.
	Fair Value of Financial Instruments
	The Company measures assets and liabilities at fair value based on an expected exit price which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.
	The following are the hierarchical levels of inputs to measure fair value:
	·	Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
	·	Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	·	Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.
	The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
	The Company’s financial instruments consisted primarily of accounts receivable, accounts payable, accrued liabilities, notes payable, and debt. The Company’s notes payable and debt approximate fair value based upon current borrowing rates available to the Company for debt with similar maturities. The carrying amounts of the Company’s financial instruments generally approximated their fair values as of September 30, 2014 and December 31, 2013, respectively, due to the short-term nature of these instruments.
	Stock-Based Compensation
	Generally, all forms of stock-based compensation, including stock option grants, warrants, restricted stock grants, and stock appreciation rights are measured at their fair value on the awards’ grant date, based on estimated number of awards that are ultimately expected to vest and expensed on a straight-line basis. Share-based compensation awards issued to non- employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based compensation, whichever is more readily determinable.
	Revenue Recognition
	The Company derives revenue primarily from sale of products. The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) product has been shipped or delivered, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.
	Depending on individual customer agreements, sales are recognized either upon shipment of products to customers or upon delivery. For all Canadian sales, which represent 3% of total sales, recognition occurs upon shipment.
	The Company records sales allowances and discounts as a direct reduction of sales. The Company grants volume incentive rebates to certain customers based on contractually agreed upon percentages once certain thresholds have been met. These volume incentive rebates are recorded as a direct reduction to sales.
	The Company has determined that customer advertising related credits are accounted for based on the guidance of ASC No. 605-50-55 (“Revenue Recognition” – Customer Payments and Incentives), which indicates that, absent evidence of benefit to the vendor, appropriate treatment requires netting these types of payments against revenues and not expensing as advertising expense.
	Advertising and Promotion
	Advertising and promotion expenses include digital and print advertising, trade show events, athletic endorsements and sponsorships, and promotional giveaways. Advertising expenses are recognized in the month that the advertising appears while costs associated with trade show events are expensed when the event occurs. For major trade shows, the expenses are recognized within the calendar year over the period in which we recognize revenue associated with sales generated at the trade show. Costs related to promotional giveaways are expensed when the product is either given out at a promotional event or shipped to the customer.
	A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts. Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions. Generally, endorsement payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract. Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the period for which the prepayment applies.
	Some of the contracts provide for contingent payments to endorsers or athletes based upon specific achievement in their sports (e.g. winning a championship). The Company records expense for these payments when the endorser achieves the specific achievement.
	Income Taxes
	Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Beginning with the adoption of Financial Accounting Standards Board (“FASB”) Interpretation No. 48, Accounting for Uncertainty in Income Taxes, (included in FASB ASC Subtopic 740-10, Income Taxes — Overall), the Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
The Company records interest and penalties related to unrecognized tax benefits in income tax expense. There were no interest or penalties related to unrecognized tax benefits for the three and nine months ended September 30, 2014 and 2013.
Foreign Currency
MusclePharm began operations in Canada in April 2012. The Canadian Dollar was determined to be the functional currency as the majority of the transactions related to the day to day operations of the business are in Canadian Dollars. At the end of the period, the financial results of the Canadian operation are translated into the U.S. Dollar, which is the reporting currency, and added to the U.S. operations for consolidated company financial results. The revenue and expense items are translated using the average rate for the month and the assets and liabilities at the month end of rate. Transactions that have completed the accounting cycle and resulted in a gain or loss related to translation are recorded in realized gain or loss due to foreign currency translation under other income and expense on the income statement. Transactions that have not completed their accounting cycle but appear to have gain or loss due to the translation process are recorded as unrealized gain or loss due to translation and recorded as accumulated other comprehensive income (loss) in the equity section on the balance sheet until such date the accounting cycle of the transaction is complete and the actual realized gain or loss is recognized.

Composition_of_Certain_Financi

Composition of Certain Financial Statement Captions	9 Months Ended
	Sep. 30, 2014
Composition Of Certain Financial Statement Captions [Abstract]	'
Composition of Certain Financial Statement Captions	'
	Note 3: Composition of Certain Financial Statement Captions
	Accounts Receivable
	Accounts receivable, net of allowance consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Accounts receivable	$	24,224,380		$	14,830,487
	Less: allowance for discounts		(851,275	)		(1,060,000	)
	Less: allowance for doubtful accounts		(153,033	)		(29,307	)
	Accounts receivable - net	$	23,220,072		$	13,741,180
	Inventory
	Inventory, net consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Raw materials inventory	$	2,221,068		$	-
	Work in process inventory		59,533			-
	Finished goods inventory		21,746,542			15,772,368
	Inventory	$	24,027,143		$	15,772,368
	Prepaid Expenses
	Prepaid expenses consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Prepaid advertising and promotion	$	855,963		$	760,740
	Prepaid professional services		195,368			74,730
	Prepaid insurance		164,089			280,878
	Prepaid software license fees		135,738			86,205
	Inventory deposit		131,413			-
	Prepaid rent		117,854			-
	Prepaid director fees		72,890			-
	Prepaid taxes		37,675			-
	Prepaid research & development fees		20,897			22,500
	Prepaid support agreements		13,500			3,499
	Prepaid license fees		-			90,623
	Prepaid - other		86,830			16,043
		$	1,832,217		$	1,335,218
	Other Current Assets
	Other current assets consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Volume rebate receivable	$	226,174		$	-
	Vendor credit		260,017			-
	Line of credit fees - net		80,664			-
	Credit card pre-payments		26,027			-
	Other current assets		44,542			40,805
		$	637,424		$	40,805
	Property and Equipment
	Property and equipment consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Furniture, fixtures and equipment	$	3,646,144		$	1,849,462
	Leasehold improvements		2,262,558			619,159
	Manufacturing and lab equipment		1,248,993			-
	Vehicles		444,065			442,300
	Displays		341,346			33,683
	Website		193,809			11,462
	Construction in process		1,433,081			1,018,509
	Total		9,569,996			3,974,575
	Less: Accumulated depreciation and amortization		(2,266,984	)		(1,360,991	)
		$	7,303,012		$	2,613,584
	Other Assets
	Other assets consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Security deposit	$	108,394		$	85,419
Prepaid advertising and promotion - long term		155,139			58,810
Other		7,049			-
	$	270,582		$	144,229
Accrued Liabilities
Accrued liabilities consisted of the following at September 30, 2014 and December 31, 2013:
	As of			As of
	30-Sep-14			31-Dec-13
Accrued payables	$	2,603,001		$	1,044,520
Employee compensation and benefits		2,235,759			1,137,681
Accrued taxes		6,430			71,771
Other		49,160			63,929
	$	4,894,350		$	2,317,901
Sales and Discounts
Sales for the three and nine months ended September 30, 2014 and 2013 were as follows:
	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Sales	$	55,634,539		$	31,080,225		$	164,168,386		$	84,519,744
Discounts and returns		(7,866,219	)		(5,736,257	)		(19,450,625	)		(11,134,551	)
Sales - Net	$	47,768,320		$	25,343,968		$	144,717,761		$	73,385,193
Discounts and returns as a percent of gross sales		14	%		18	%		12	%		13	%
The Company has an informal seven day right of return for products. There were nominal returns for the three and nine months ended September 30, 2014 and 2013.
The Company offers discounts and sales allowances for: volume rebates, product promotions, early payments, and other discounts and allowances. The Company accounts for sales discounts and allowances over the period they are earned. Because of the inherent uncertainty surrounding volume rebate programs and product promotions that are based on sales, actual results could generate liabilities greater or less than the amounts estimated and recorded.
Cost of Sales
Cost of sales for MusclePharm and MusclePharm Canada represent costs directly related to the production, manufacturing and freight-in of the Company’s products purchased from third party manufacturers.  The Company mainly ships customer orders from its distribution center in Franklin, Tennessee. The facility is operated with the Company’s equipment and employees, and inventory is owned by the Company. The Company also utilizes contract manufacturers to drop ship product directly to customers.
Cost of sales for products produced by Biozone Labs consist of raw material, direct labor, freight-in, and other supply and equipment rental expenses.  The Company mainly ships customer orders from its distribution center in Pittsburg, California.

Concentrations

Concentrations	9 Months Ended
	Sep. 30, 2014
Risks And Uncertainties [Abstract]	'
Concentrations	'
	Note 4:  Concentrations
	Accounts Receivable
	At September 30, 2014 and December 31, 2013, the Company had the following concentrations of accounts receivable:
	Customer		As of September 30, 2014			As of December 31, 2013
	Bodybuilding.com			16	%		14	%
	B			10	%	*		%
	C			10	%	*		%
	D		*		%		24	%
	E		*		%		16	%
	*	Less than 10% of total accounts receivable
	Revenue
	The Company had the following concentrations of revenues:
			Three Months Ended September 30,
	Customer		2014			2013
	Bodybuilding.com			14	%		32	%
	B			10	%	*		%
	C		*		%		10	%
			Nine Months Ended September 30,
	Customer		2014			2013
	Bodybuilding.com			14	%		30	%
	B		*		%	*		%
	C		*		%		11	%
	*	Less than 10% of gross sales
	Vendors
	The Company uses five non-affiliated principal contract manufacturers of our products. We have quality control and manufacturing agreements in place with our primary manufacturers to support our growth and ensure consistency in production and quality. The agreements ensure products are manufactured to the Company’s specifications and the contract manufacturers will bear the costs of any recalled product due to defective manufacturing.
	The Company had the following concentration of purchases with contract manufacturers:
			Three Months Ended September 30,
	Vendor		2014			2013
	A			58%			27%
	B			36%			72%
			Nine Months Ended September 30,
	Vendor		2014			2013
	A			51%			22%
	B			45%			78%

Financial_Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Financial Instruments	'
	Note 5:  Financial Instruments
	The following is a summary of financial assets and liabilities:
		As of September 30,		As of December 31,
		2014		2013
	Assets
	Debt securities - FUSE convertible notes (Level 2)	$	-	$	259,715
	Derivative instruments - FUSE warrants (Level 2)		-		119,248
			-		378,963
	Liabilities
	Derivative liabilities  - Series D shares (Level 2)	$	-	$	1,147,330
	On April 2, 2014, the Company entered into a security purchase agreement and sold the Fuse convertible note and warrants for an aggregate purchase price of $215,000.
	Also on April 2, 2014 the remaining outstanding shares of Series D preferred stock were converted into common shares thereby eliminating the remaining derivative liability for the embedded conversion option as of that date.

Investment_in_Debt_Securities

Investment in Debt Securities	9 Months Ended
	Sep. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Debt Securities	'
	Note 6: Investment in Debt Securities
	On August 26, 2013, the Company purchased, for an aggregate $2,000,000, a secured convertible promissory note from Biozone Pharmaceuticals, Inc.  (“Biozone”) (OTC:BZNE) that matured one year from the date of issuance, and certain derivative instruments (Note 7), the value was recorded as a discount to the note to be accreted over the note’s term. In addition, a change of control put option was identified but was not recorded as a derivative because the value was determined to be deminimus. The promissory note bears interest at a rate of 10% per annum, convertible at any time prior to the maturity date into 10,000,000 shares of Biozone common stock at the conversion rate of $0.20 per share, and contains certain put and call features. The conversion into Biozone Common Stock is restricted by a beneficial ownership limitation of 4.99% of the number of the common stock outstanding after giving effect to the issuance of common stock issuable upon conversion. This conversion limit can be changed upon at least 60 days’ notice.
	The Company classified this note as an available-for-sale security and engaged an independent third party firm to value the note and its embedded conversion features each reporting period.  Changes in the reported value of the note are included as a component of other comprehensive income.  The note had a fair value on the purchase date of $1,955,462, which was purchased at a $44,538 premium.  The premium was netted against the discount of $1,248,292 attributable to the derivative instrument and was accreted to interest income over the stated maturity of the note.  The debt security was recorded at fair value net of any recorded discount not yet accreted.
	The following summarizes the Company’s marketable securities activity for the year ended December 31, 2013:
		Convertible
		Note
	FV of debt security on August 26, 2013	$	1,955,462
	Premium on purchase date		44,538
	Discount for value of derivative instrument		-1,248,292
	Accretion of net discount		1,248,292
	Conversion of principal		-1,000,000
	Repayments received		-1,000,000
	Balance – December 31, 2013	$	-
	As of September 30, 2014 the Company had no investment in debt securities outstanding.

Derivative_Instrument

Derivative Instrument	9 Months Ended
	Sep. 30, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative Instrument	'
	Note 7: Derivative Instrument
	In conjunction with the purchase of the convertible promissory note discussed in Note 6, the Company received a callable warrant to purchase up to 10,000,000 shares of Biozone at an exercise price of $0.40 with an expiration date of 10 years from the date of issuance. The initial value of the warrant was $1,248,292 and was recorded as a discount against the note. The exercise of the warrant was limited by a beneficial ownership limitation of 4.99% of the number of the common shares outstanding in Biozone after giving effect to the exercise of the warrant.
	The Company engaged an independent third party firm to value the warrant. The warrant was valued using a binomial lattice pricing model.  This model considers price volatility, time, and dilutive effect of exercising. The pricing model assumes a volatility of 70% at the dates of purchase and period end.

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Note 8: Debt
	Debt consists of the following:
		As of September 30,			As of December 31,
		2014			2013
	Revolving line of credit	$	8,000,000		$	2,500,000
	Notes payable		45,600			59,600
	Auto loan - secured		-			2,902
	Total debt		8,045,600			2,562,502
	Less: current portion		(8,045,600	)		(2,562,502	)
	Long term debt	$	-		$	-
	Line of Credit
	Lines of credit consisted of the following activity:
		ANB Bank			US Bank
	Balance - December 31, 2013	$	-		$	2,500,000
	Borrowing		8,000,000			-
	Principal repayments		-			(2,500,000	)
	Balance - September 30, 2014	$	8,000,000		$	-
	On September 12, 2014, the Company entered into a line of credit facility providing up to $8,000,000 of borrowing. The line of credit matures on September 12, 2017 and accrues interest at the prime rate plus 2%, currently 5.25%. The note is secured by the Company’s inventory, accounts receivable, intangible assets, and equipment.  In conjunction with entering into the credit line, the Company paid $81,800 in debt issuance costs, which are being amortized to interest expense over the term on an effective interest rate basis.
	The facility contains negative covenants and restrictions on actions by the Company including, without limitation, restrictions on indebtedness, liens, investments, loans, consolidation, mergers, dissolution, asset dispositions outside the ordinary course of business, change in business, transactions with affiliates, bankruptcy, insolvency, change of control and changes relating to indebtedness. In addition, the facility requires compliance by the Company with the following covenants:
	·	during each quarter the outstanding principal balance of the line of credit must be reduced and maintained below $3,000,000 for a minimum of 14 non-consecutive days,
	·	without prior written consent, the Company cannot incur additional debt obligations during any 12-month period that, in the aggregate, exceeds $250,000, or any individual debt obligation that exceeds $100,000,
	·	maintain a minimum market capitalization of $65,000,000,
	·	without prior written consent, the Company cannot enter any cash transaction, other than in the ordinary course of business, in excess of $1,000,000,
	·	for each calendar quarter, maintain quarterly average balance in excess of $1,200,000,
	·	maintain a debt service coverage ratio of at least 2.0:1, and
	·	maintain a current ratio of at least 1.5:1.
	The Company was in compliance with these covenants as of September 30, 2014.
	On December 24, 2013, the Company entered into a revolving line of credit with U.S. Bank, N.A. in the amount of $2,500,000. The line of credit matures on September 15, 2014 and accrued interest at the prime rate plus 2%, which is payable monthly. The note is secured by a $2,500,000 savings account held at U.S. Bank, N.A. and disclosed as restricted cash in the December 31, 2013 Consolidated Balance Sheet. On May 12, 2014, the Company repaid the outstanding balance of the line of credit with the restricted cash balance that was securing the debt, and terminated the line of credit agreement. The line of credit will not be available for further borrowing.
	Notes Payable
	Notes payable consisted of the following activity:
	Balance - December 31, 2013	$	59,600
	Principal repayments		(14,000	)
	Balance - September 30, 2014	$	45,600
	Debt in default of $45,600 and $59,600 at September 30, 2014 and December 31, 2013, respectively, is included as a component of short-term debt. Debt in default is related to certain convertible notes issued in 2012 and prior where the notes were never converted to common stock or principal repaid. The Company is in the process of contacting the note holders and negotiating settlement of the notes.
	Vehicle Loan
	Vehicle loan account consisted of the following activity and terms:
	Balance - December 31, 2013	$	2,902
	Principal repayments		(2,902	)
	Balance - September 30, 2014	$	-
	At December 31, 2013, the interest rate associated with this loan was 6.99%. The three final monthly payments of $1,008 per were paid in first quarter 2014.

Derivative_Liabilities

Derivative Liabilities	9 Months Ended
	Sep. 30, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative Liabilities	'
	Note 9: Derivative Liabilities
	The Company identified conversion features embedded within Series D Preferred Stock issued in January 2013. The Company has determined that the features associated with the embedded conversion option should be accounted for at fair value as a derivative liability as the Company could not determine if a sufficient number of shares would be available to settle all transactions.
	The fair value of the conversion feature is summarized as follows:
	Derivative liability - December 31, 2013	$	1,147,330
	Fair value mark to market adjustment for equity instruments		(373,944	)
	Conversion instruments exercise		(773,386	)
	Derivative liability - September 30, 2014	$	-
	The Company recorded the day one value of derivative contracts associated with the Series D preferred stock issuance against gross proceeds raised, and expensed immediately the remaining value of the derivative as it exceeded the gross proceeds of the offering. The Company recorded a derivative expense of $0 and $96,913 for the nine months ended September 30, 2014 and 2013, respectively.
	On April 2, 2014, the remaining outstanding shares of Series D preferred stock were converted into common shares thereby eliminating the remaining derivative liability for the embedded conversion option as of that date. Of the derivative liability that was eliminated, $773,254 was reclassified to Additional paid-in capital in our Consolidated Balance Sheets.

Restricted_Stock

Restricted Stock	9 Months Ended
	Sep. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Restricted Stock	'
	Note 10: Restricted Stock
	In November 2012, the Company granted 129,413 restricted stock units to certain executives. Each restricted stock unit represents a contingent right to receive one share of the Company’s common stock upon vesting. The value of this award at the grant date was $449,900 and will be amortized over the vesting periods such that each tranche of restricted stock units will be fully amortized at the date of vesting. The restricted stock units vest as follows: 43,137 on January 1, 2013, 43,138 shares on January 1, 2014, and 43,138 shares on December 1, 2014. As of September 30, 2014, 86,275 restricted stock units have vested and the unamortized portion of this award is $37,800.
	In June 2013, the Company approved a restricted stock award to certain key employees, officers and directors for 1,550,000 shares. The shares were issued upon the award’s approval with ownership rights conveyed upon vesting. The value of this award at the grant date was $17,065,500. Of these shares, the Company estimates that 1,500,200 shares will fully vest for a total value of $16,517,202. This amount will be amortized over the vesting periods such that each tranche’s estimated shares of restricted stock will be fully amortized at the dates of vesting. The award vests in two tranches with 17% vesting December 31, 2013 and the remaining 83% vesting December 31, 2015 with the exception of certain executives under employment agreements that terminate prior to December 31, 2015. These awards will be amortized over the remaining term of their employment agreements. As of September 30, 2014, 263,500 shares have vested and the unamortized portion of this award is $7,310,640.
	In December 2013, the Company granted the independent members of the Board of Directors a restricted stock grant of 19,364 shares as part of the annual director’s compensation plan. The awarded shares were issued with ownership rights to be conveyed upon vesting. The value of this award at the grant date was $152,000, and will be amortized over the vesting periods. The restricted stock award will vest in three equal tranches on July 1, 2014, July 1, 2015, and July 1, 2016. As of September 30, 2014, 6,456 shares have vested and the unamortized portion of the awards was $88,658.
	On March 17, 2014, the Company granted the independent members of the Board of Directors a restricted stock grant of 48,856 shares as part of the annual director’s compensation plan. The awarded shares were issued with ownership rights to be conveyed upon vesting. The value of this award at the grant date was $320,007, and will be amortized over the service period, which is January 1 – December 31, 2014. The restricted stock award will vest in three equal tranches on March 17, 2014, March 17, 2015, and March 17, 2016. As of September 30 2014, 16,284 shares have vested and the unamortized portion of the awards is $80,220.
	On May 6, 2014, the Company granted 120,000 shares of restricted stock awards to certain employees under the June 2013 employee stock grant plan. The awarded shares were issued with ownership rights to be conveyed upon vesting. The value of this award on the grant date was $1,137,600, and will be amortized over the vesting periods. The restricted award will vest in five equal tranches on December 31, 2014, 2015, 2016, 2017, and 2018. As of September 30, 2014, no shares have vested and the unamortized portion of the award is $995,400.
	Total compensation expense for these awards recognized during the three months ended September 30, 2014 and 2013 was $2,317,818, and $1,513,701, respectively. For the nine months ended September 30, 2014 and 2013, the total compensation expense for these awards was $6,837,585 and $1,588,068, respectively, and is included in operating expenses.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders Equity Note [Abstract]	'
Stockholders' Equity	'
	Note 11: Stockholders’ Equity
	Common Stock
	During the nine months ended September 30, 2014, the Company issued the following common stock:
			Shares				Value				Range of Value
											per Share
	Transaction Type										($)
	Conversion of Series D preferred stock to common stock			263,000			$	773,517				2.94
	Executive/Board of Director compensation			66,878				315,991			3.48 - 8.70
	Stock issued for services			476,853				5,402,300			11.19 - 13.41
	Stock issued for Biozone Labs acquisition			1,200,000				9,840,000				8.2
	Total			2,006,731			$	16,331,808			2.94 - 13.41
	The fair value of all stock issuances above is based upon either the quoted closing trading price on the date of issuance or the value of derivative instrument at the date of conversion. See Note 16 for further details of the Biozone Labs acquisition.
	Earnings (Loss) Per Share
	Basic net earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common stock, common stock equivalents and potentially dilutive securities outstanding during each period.
	The Company uses the “treasury stock” method to determine whether there is a dilutive effect of outstanding option and warrant contracts. For the three and nine months ended September 30, 2013, the Company reflected net loss and a dilutive net loss, and the effect of considering any common stock equivalents would have been anti-dilutive for the period. Therefore, separate computation of diluted earnings (loss) per share is not presented for the three and nine months ended September 30, 2013.
	The Company has the following common stock equivalents as of September 30, 2014 and 2013, respectively:
		As of September 30,
		2014				2013
	Stock options (exercise price - $425/share)		472				472
	Warrants (exercise price - $4 /share)		-				288,000
	Warrants (exercise price - $1,275/share)		89				89
	Warrants (exercise price - $11.90/share)		100,000				-
	Unvested restricted stock		1,495,117				1,647,581
	Total common stock equivalents		1,595,678				1,936,142
	The following is a reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the three and nine months ended September 30, 2014 and 2013, respectively:
		Three months ended								Nine months ended
		September 30,								September 30,
		2014				2013				2014				2013
	Net income (loss)	$	602,618			$	(3,945,836	)		$	2,404,338			$	(13,729,627	)
	Weighted average number of common shares		11,032,996				8,475,084				10,652,781				6,626,125
	outstanding
	Incremental shares from the assumed exercise of		1,579,900				-				1,459,236				-
	dilutive agreements
	Diluted common shares outstanding		12,612,896				8,475,084				12,112,017				6,626,125
	Earnings (loss) per shares - basic	$	0.05			$	(0.47	)		$	0.23			$	(2.07	)
	Earnings (loss) per shares - diluted	$	0.05			$	(0.47	)		$	0.2			$	(2.07	)
	Stock Options
	There was no stock option activity for the three or nine months ended September 30, 2014. For the three and nine months ended September 30, 2013, the Company had forfeitures of 198 and 1,375 options, respectively.
	Stock Warrants
	A summary of warrant activity for the Company for the nine months ended September 30, 2014 is as follows:
			Number of Warrants				Weighted Average
							Exercise Price
	Outstanding - December 31, 2013			263,089			$	4.43
	Granted			100,000				11.9
	Exercised			(263,000	)			4
	Balance as September 30, 2014			100,089			$	13.02
	Warrants Outstanding																Warrants Exercisable
	Range of				Number				Weighted Average				Weighted Average				Number		Weighted		Intrinsic Value
	Exercise Prices				Outstanding				Remaining				Exercise Price				Exercisable		Average
									Contractual Life (in										Exercise Price
									years)
	$	11.9				100,000				4.79			$	11.9				8,336	$	11.9	$	130,000
		1,275.00				89				0.79				1,275.00				89		1,275.00		-
	Treasury Stock
	During the quarter ended September 30, 2014, the Company purchased 100,000 shares of its common stock for the total sum of $1,362,881, or an average of $13.63 per share. This repurchase was completed under a stock repurchase plan approved by the MusclePharm Board of Directors in December 2013, which allows the Company to repurchase up to $5 million worth of stock for a one year period beginning on December 10, 2013. These repurchased shares are accounted for under the cost method and are included as a component of treasury stock in the Consolidated Balance Sheets.
	Additionally, the Company received 350,000 shares held in escrow related to the Biozone Labs asset purchase as more fully described in Note 16.  These shares were returned to the Company and are being accounted for as treasury stock.

Commitments_Contingencies_and_

Commitments, Contingencies and Other Matters	9 Months Ended
	Sep. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments, Contingencies and Other Matters	'
	Note 12: Commitments, Contingencies and Other Matters
	Operating Leases
	The Company leases office and warehouse facilities under operating leases which expire at various dates through 2029. The amounts reflected in the table below are for the aggregate future minimum lease payments under non-cancelable facility operating leases. Under lease agreements that contain escalating rent provisions, lease expense is recorded on a straight-line basis over the lease term. Rent expense for the nine months ended September 30, 2014 and 2013 amounted to $988,550 and $446,943, respectively.
	As of September 30, 2014, future minimum lease payments are as follows:
	Years Ending December 31,
	2014 (remaining 3 months)	$	309,727
	2015		1,105,030
	2016		898,311
	2017		841,118
	2018		838,246
	Thereafter		3,519,391
	Total minimum lease payments	$	7,511,823
	Capital Leases
	The Company leases manufacturing and warehouse equipment under capital leases which expire at various dates through 2017. As of September 30, 2014, the Company had $295,778 in leased assets included in furniture, fixtures, and equipment and manufacturing and lab equipment balances of property and equipment in the Consolidated Balance Sheets. The accumulated depreciation on leased assets as of September 30, 2014 was $22,619. Short term capital lease liabilities of $97,925 are included as a component of current liabilities, and the long-term capital lease liabilities of $135,689 are included as a component of long term liabilities in the Consolidated Balance Sheets.
	As of September 30, 2014 and December 31, 2013, the Company had an outstanding balance on capital leases of $233,613 and $81,292, respectively. The amounts reflected in the table below are for the aggregate future minimum lease payments under equipment lease agreements.
	As of September 30, 2014, future minimum lease payments are as follows:
	Years Ending December 31,
	2014 (remaining 3 months)	$	28,300
	2015		114,254
	2016		101,553
	2017		19,352
	Total minimum lease payments		263,459
	Less amounts representing interest		(29,846	)
	Present value of minimum lease payments	$	233,613
	Contingencies
	For legal proceedings, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies.
	The Company and its subsidiaries are involved in litigation matters and claims in the normal course of business. In the past, the Company and its subsidiaries have litigated these matters. The Company expects it or its subsidiaries will be involved in legal proceedings in the future. These existing and any future legal actions may harm the Company’s business. Litigation could severely disrupt or shut down the business operations or strategic partners of the Company’s subsidiaries, which in turn would significantly harm ongoing relations with them and cause the Company to lose revenues. The costs associated with legal proceedings are typically high, relatively unpredictable and not completely within the Company’s control. These costs may be materially higher than expected, which could adversely affect the Company’s operating results and lead to volatility in the price of its common stock. Whether or not determined in the Company’s favor or ultimately settled, litigation diverts managerial, technical, legal and financial resources from the Company’s business operations. Furthermore, an adverse decision in any of these legal actions could subject the Company to significant liabilities, lost revenue, negatively impact the Company’s stock price or its business and consolidated financial position, results of operations or cash flows.
	Additionally, as a manufacturer of nutritional supplements and other consumer products that are ingested by consumers, the Company may be subject to various product liability claims. Although we have not had any material claims to date, it is possible that current and future product liability claims could have a material adverse effect on our business or financial condition, results of operations or cash flows. The Company currently maintains product liability insurance with a deductible/retention of $10,000 per claim with an aggregate cap on retained loss of $20,000,000. At September 30, 2014, the Company had not recorded an accrual for product liability claims.
	Sponsorship and Endorsement Contract Liabilities
	The Company has various non-cancelable endorsement and sponsorship agreements with terms expiring through 2018. The total value of outstanding payments as of September 30, 2014 was $34,142,017. The total outstanding payments are as follows:
	Outstanding Payments	2014			2015		2016		2017		2018		Total
	Endorsement	$	1,864,000		$	8,354,934	$	6,526,833	$	6,600,000	$	3,500,000	$	26,845,767
	Sponsorship		1,153,750			4,905,000		1,137,500		100,000		-		7,296,250
	Total	$	3,017,750		$	13,259,934	$	7,664,333	$	6,700,000	$	3,500,000	$	34,142,017
	SEC Investigation
	In July 2013, the Company received a formal order of investigation of the Company from the Denver Regional Office of the Securities and Exchange Commission. As a result of that formal order, the Company has conducted a review of its internal controls, disclosures of related party transactions, settlements of claims including share issuance, executive compensation, and disclosure of perquisites for the periods of 2010, 2011, 2012, and 2013. There can be no assurance that these are the only subject matters of concern, what the nature or amounts in question will be, or that these are the only periods under review. As of September 30, 2014 and the date of this report, there have been no changes in the status of the investigation.

Defined_Contribution_Plan

Defined Contribution Plan	9 Months Ended
	Sep. 30, 2014
Compensation And Retirement Disclosure [Abstract]	'
Defined Contribution Plan	'
	Note 13: Defined Contribution Plan
	The Company established a 401(k) Plan (the “401(k) Plan”) for eligible employees of the Company. Generally, all employees of the Company who are at least twenty-one years of age and who have completed six months of service are eligible to participate in the 401(k) Plan. The 401(k) Plan is a defined contribution plan that provides that participants may make voluntary salary deferral contributions, on a pretax basis, of up to $17,500 for 2014 (subject to make-up contributions) in the form of voluntary payroll deductions. The Company may make discretionary contributions. During the nine months ended September 30, 2014 and 2013 the Company’s matching contribution was $220,505 and $44,940, respectively.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure	'
	Note 14: Related Party Transactions
	Ryan DeLuca, the Chief Executive Officer of Bodybuilding.com, is the brother of Jeremy DeLuca, MusclePharm’s EVP, MusclePharm Brand and Global Business Development. The Company maintained a business relationship with Bodybuilding.com prior to hiring Mr. DeLuca. The Company does not offer preferential pricing of our products to Bodybuilding.com based on these relationships. Sales of products to Bodybuilding.com were $7,852,060 and $9,694,910, respectively, for the three months ended September 30, 2014 and 2013; and $23,352,058 and $24,648,755 for the nine months ended September 30, 2014 and 2013, respectively. The Company had approximately $3,775,939 and $2,051,265 in trade receivables with Bodybuilding.com as of September 30, 2014 and December 31, 2013, respectively. The Company purchased marketing services from Bodybuilding.com during the three and nine months ended September 30, 2014 in the amount of $349,999 and $1,038,884, respectively.
	The Company leases office and warehouse facility in Hamilton, Ontario, Canada from 2017275 Ontario Inc., which is a company owned by Renzo Passaretti, VP and General Manager of MusclePharm Canada Enterprises Corp, our wholly owned Canadian subsidiary. For the three and nine months ended September 30, 2014, we paid rent of $22,948 and $63,962, respectively, and for the three and nine months ended September 30, 2013, we paid rent of $18,886 and $57,857, respectively. The lease expires March 31, 2016.
	On October 16, 2013, the Company entered into an Office Lease Agreement with Frost Real Estate Holdings, LLC, a Florida limited liability company owned by Dr. Phillip Frost, a significant shareholder. Pursuant to the lease, the Company rents 1,437 square feet of office space for an initial term of three years, with an option to renew the lease for an additional three- year term. For the three and nine months ended September 30, 2014, we paid rent of $14,358 and $41,186, respectively.
	During the nine months ended September 30, 2014, the Company purchased split dollar life insurance policies on certain key executives. These policies provide a split of 50% of the death benefit proceeds to the Company and 50% to the officer’s designated beneficiaries.

Endorsement_Agreement

Endorsement Agreement	9 Months Ended
	Sep. 30, 2014
Endorsement Agreement [Abstract]	'
Endorsement Agreements	'
	Note 15:  Endorsement Agreements
	Arnold Schwarzenegger
	On July 26, 2013, the Company entered into an Endorsement Licensing and Co-Branding Agreement by and among, the Company, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. Under the terms of the agreement, Mr. Arnold Schwarzenegger will co-develop a special Arnold Schwarzenegger product line and will be co-marketed under Mr. Schwarzenegger’s name and likeness.
	In connection with this agreement, the Company also issued Marine MP, LLC fully vested restricted shares of common stock with an aggregate market value of $8,541,000. As of September 30, 2014 and December 31, 2013, the amount of unamortized stock compensation expense related to this agreement was $5,171,400 and $7,300,800, respectively. The shares are being amortized over the original three-year term of the agreement. The current and non-current portions of this unamortized stock compensation are included as a component of prepaid stock compensation in the Consolidated Balance Sheets.
	Tiger Woods
	Effective July 1, 2014, the Company entered into an Endorsement Agreement with ETW Corp. Under the terms of the agreement, Tiger Woods will endorse certain of the Company’s products and use a golf bag during all professional golf play which prominently displays the MusclePharm name and logo.
	In conjunction with this agreement, on July 3, 2014, the Company issued 446,853 shares of the Company’s restricted common stock to ETW Corp with an aggregate market value of $5,000,000. As of September 30, 2014, the amount of unamortized stock compensation expense related to this agreement was $4,684,932. The shares are being amortized over the original four-year term of the agreement. The current and non-current portions of the unamortized stock compensation are included as a component of prepaid stock compensation in the Consolidated Balance Sheets.
	Johnny Manziel
	Effective July 15, 2014, the Company entered into an Endorsement Agreement for the services of Johnny Manziel. As part of this agreement, the Company issued warrants to purchase 100,000 shares of MusclePharm common stock at an exercise price of $11.90 per share. These warrants vest monthly over a period of 24 months beginning August 15, 2014, and have a five-year contractual term.  For the three and nine month periods ended September 30, 2014, the Company recognized stock based compensation expense of $69,189 related to these warrants, included as a component of advertising and promotion expense in the Consolidated Statements of Operations.  The Company used the Black-Scholes pricing model to determine the estimated fair value of the warrants, with the following assumptions:  expected life of five years, risk free interest rate of 1.70%, dividend yield of 0.00%, and expected volatility of 55%.

Biozone_Labs_Acquisition

Biozone Labs Acquisition	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Biozone Acquisition	'
	Note 16:  Biozone Labs Acquisition
	On January 2, 2014, the Company completed its acquisition of BioZone Pharmaceuticals, Inc. for $7,110,730 in MusclePharm common stock, net of an embedded derivative to repurchase common stock valued at $444,000 and a net contingent asset of $1,498,053.
	The purchase price under the asset purchase agreement was 1.2 million shares of the Company’s common stock of which 600,000 shares were issued to the seller and 600,000 shares were placed into escrow for a period of nine months to cover indemnification obligations.  These 600,000 escrowed shares are also subject to repurchase from the escrow for $10.00 per share in cash resulting in the previously mentioned embedded derivative.  The initial 600,000 were issued to the seller upon closing and are subject to a lockup agreement which permits private sales (subject to the lockup and certain leak out provisions).
	As of September 30, 2014 the Company completed the final fair value analysis of all assets and liabilities acquired, and sent a notice of claim to the seller and escrow agent for the shares being held in escrow.  In conjunction with the fair value analysis, the Company recognized a bargain purchase gain of $3,685,568, as the fair value of assets and liabilities acquired exceeded the total amount of consideration as Biozone was experiencing a distressed financial situation.  After the return of shares held in escrow, the Company also recognized a $1,579,286 gain as reimbursement of expenses and conclusion of a contingent asset and liability related to one of the leased buildings that Biozone Labs operates.
	The bargain purchase gain and contingent asset gain are included as a component of Other Income (Expense) in the Consolidated Statements of Operations.
	The Biozone Labs asset purchase is considered an acquisition of a business and was accounted for in accordance with accounting guidance for business combinations. The acquired assets and liabilities have been recognized at their estimated fair value, and the purchase price has been allocated to the tangible and intangible assets acquired and liabilities assumed. MusclePharm contracted a third party valuation firm to determine the fair value at the date of purchase of all identifiable tangible and intangible assets purchased in the acquisition. Based upon the fair values, the purchase price allocation is as follows:
	Purchase Price Allocation
	Net Tangible Assets
	Current assets	$	3,183,152
	Property & equipment		1,859,066
	Liabilities assumed		(1,378,920	)
	Total net tangible assets acquired		3,663,298
	Identified Intangible Assets
	Customer relationships		3,130,000
	Technology		2,158,000
	Brand		1,776,000
	Non-compete agreements		69,000
	Total identified intangible assets acquired		7,133,000
	Bargain Purchase Gain		(3,685,568	)
	Total	$	7,110,730
	Unaudited Pro Forma Income Statement
	The accompanying consolidated statements of operations include the results of the Biozone Labs acquisition from the acquisition date of January 2, 2014. The Company has determined that there were no significant transactions during the one day which is not presented in the accompanying consolidated statement of operations for the nine months ended September 30, 2014 and has therefore not presented the pro forma effects of the acquisition for this period. The unaudited pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on January 1, 2013 for the three and nine months ended September 30, 2013 is as follows:
	Three Months Ended September 30, 2013
		MusclePharm			BioZone			Combined			Pro Forma				MusclePharm
		Corp.			Pharmaceuticals			Before Pro			Adjustments				Corp.
					Inc.			Forma							Pro Forma
								Adjustments
	Sales - net	$	25,343,968		$	2,086,985		$	27,430,953		$	-			$	27,430,953
	Net loss		(3,945,836	)		1,625,451			(2,320,385	)		(70,144	)	(a)		(2,390,529	)
	Net loss per share - basic and diluted	$	(0.49	)		-			-			-			$	(0.29	)
	Weighted average number of		8,125,084			-			-			-				8,125,084
	common shares used in per share
	calculations - basic and diluted
	Nine Months Ended September 30, 2013
								Combined
					BioZone			Before Pro							MusclePharm
		MusclePharm			Pharmaceuticals			Forma			Pro Forma				Corp.
		Corp.			Inc.			Adjustments			Adjustments				Pro Forma
	Sales - net	$	73,385,193		$	5,764,116		$	79,149,309		$	-			$	79,149,309
	Net loss		(13,729,627	)		(194,900	)		(13,924,527	)		(218,162	)	(a)		(14,142,689	)
	Net loss per share - basic and diluted	$	(2.19	)		-			-			-			$	(2.25	)
	Weighted average number of		6,276,125			-			-			-				6,276,125
	common shares used in per share
	calculations - basic and diluted
	(a)Pro forma adjustment to eliminate historical seller depreciation expense and record depreciation and amortization expense resulting from the assets acquired.
	The above unaudited pro forma results include adjustments for depreciation of property and equipment and amortization of acquired intangible assets. The unaudited pro forma information as presented above is for informational purposes only and is not necessarily indicative of results of operations that would have been achieved if the acquisition had taken place at the date identified.

Intangible_Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	Note 17:  Intangible Assets
	Intangible assets consist of the following:
									Weighted
		As of September 30, 2014							average
				Accumulated					amortization
		Gross Assets		Amortization			Net Assets		period (years)
	Amortized intangible assets
	Customer relationships	$	3,130,000	$	(156,500	)	$	2,973,500		14.26
	Technology		2,158,000		(202,313	)		1,955,687		7.26
	Non-compete agreements		69,000		(25,875	)		43,125		1.25
	Patents		52,501		(19,596	)		32,905		2.77
	Trademarks		35,000		(17,818	)		17,182		2.25
	Brand		1,776,000		-			1,776,000		19.27
	Domain name		67,665		-			67,665		-
	Total intangible assets		7,288,166		(422,102	)		6,866,064
	Amortization expense for the three months ended September 30, 2014 and 2013 was $(156,194) and zero, respectively, and for the nine months ended September 30, 2014 and 2013 was $422,102 and zero, respectively.  Due to the finalization of the valuation related to the purchased assets of Biozone Labs during the quarter, the Company recognized a cumulative adjustment to amortization of intangible assets resulting in a benefit of $429,790.  Amortization expense is included in operating expenses in the Consolidated Statement of Operations.
	As of September 30, 2014, the estimated future amortization expense of intangible assets is as follows:
	2014 (remaining 3 months)	$	222,349
	2015		622,061
	2016		584,083
	2017		571,497
	2018		569,491
	Thereafter		4,296,583
	Total amortization expense	$	6,866,064

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Note 18: Subsequent Events
	The Company evaluates subsequent events for disclosure that may have occurred between the financial statement date and the date of the filing of Form 10-Q with the Securities and Exchange Commission.  Below is a list of material subsequent events through the date of filing:
	Officers and Director Changes
	Effective October 1, 2014, the Board of Directors appointed Andrew Lupo to serve as a member of the Company’s Board of Directors and as Chairman of the Company’s Compensation Committee. The Board of Directors has determined that Mr. Lupo is an independent director pursuant to the rules of the NASDAQ Stock Market.
	Mr. Lupo will be compensated for his services at the same level as the other non-employee directors of the Company, pursuant to the Company’s Non-Employee Director Compensation Program.  There is no family relationship between Mr. Lupo and any of our other officers and directors.
	On October 14, 2014, Mr. Sydney Rollock resigned his position as Chief Marketing and Sales Officer of MusclePharm Corporation.  Simultaneously with Mr. Rollock’s resignation as an employee of the Company, Mr. Rollock and the Company entered into a Separation and Release of Claims Agreement pursuant to which Mr. Rollock ended his employment with the Company.  Pursuant to his release agreement, Mr. Rollock shall vest in all unvested restricted stock.
	Mr. Rollock’s resignation was not as a result of any disagreements with the Company’s operations, policies or practices.
	CoCrystal Pharma Stock Repurchase
	The Company purchased 250,000 shares of the Company’s common stock, which were being held in escrow pursuant to the Biozone Labs asset purchase agreement, for an aggregate purchase price of $2,500,000.  These shares will be accounted for as Treasury Shares upon repurchase.
	Stock Grant to Employees and Directors
	In conjunction with the shareholder annual meeting, the Board of Directors granted 1,230,000 restricted shares on October 1, 2014 to certain executives and other employees.  The shares vest as follows: 60% on December 31, 2016, 20% on December 31, 2017, and 20% on December 31, 2018.
	On October 15, 2014, the Company granted a total of 4,748 shares of restricted to stock to two new members of the MusclePharm Board of Directors, who joined the Board during 2014 as part of the annual director’s compensation plan.  These shares were vested upon issuance.
	Appointment of Chairman of the Disclosure Committee and Risk Management Officer
	On November 6, 2014 the Board of Directors approved the appointment of John Price, Executive Vice President, as the Chairman of the Company’s Disclosure Committee and Risk Management Officer.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries MusclePharm Canada Enterprises Corp (“MusclePharm Canada”) and Biozone Laboratories, Inc. (“Biozone Labs”). MusclePharm Canada began operations in April 2012 and Biozone Labs was acquired in January 2014. All intercompany accounts and transactions have been eliminated upon consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates and assumptions that require management’s most significant, difficult, and subjective judgment include the recognition and measurement of allowance for doubtful accounts, inventory write down, derivatives, allocation of acquisition purchase price, warrant and option valuation, and sales discounts and allowances reserve among others. Actual results experienced by the Company may differ from management’s estimates.
Risks and Uncertainties	'
	Risks and Uncertainties
	The Company operates in an industry that is subject to rapid change and intense competition. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory, industry adverse publicity and other risks, including the potential risk of business failure.
Recent Accounting Pronouncements	'
	Recently Adopted Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists.” This ASU provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carry forward or a tax credit carry forward exists. Under the ASU, the Company’s unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carry forward or a tax credit carry forward. This ASU applies to all entities that have unrecognized tax benefits when a net operating loss carry-forward, a similar tax loss, or a tax credit carry-forward exists at the reporting date.  The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this ASU did not have a material impact on the Company's financial statements.
	Recent Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation – Stock Compensation” (“ASC 718”), as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material effect on the Company’s unaudited consolidated financial statements or disclosures.
	In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers" (“ASU 2014-09”), which provides guidance for revenue recognition. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets and supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition- Construction-Type and Production-Type Contracts.” ASU 2014-09’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company beginning January 1, 2017 and, at that time, the Company may adopt the new standard under the full retrospective approach or the modified retrospective approach. Early adoption is not permitted. The Company is currently evaluating the method and impact the adoption of ASU 2014-09 will have on the Company’s unaudited condensed consolidated financial statements and disclosures.
	In April 2014, the FASB issued ASU 2014-08, "Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity." ASU 2014-08 changes the criteria for reporting a discontinued operation. Under the new pronouncement, a disposal of a part of an organization that has a major effect on its operations and financial results is a discontinued operation. The Company is required to adopt ASU 2014-08 prospectively for all disposals or components of its business classified as held for sale during fiscal periods beginning after December 15, 2014. The adoption of ASU 2014-08 is not expected to have a material effect on the Company’s unaudited consolidated financial statements or disclosures.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments purchased with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents. At September 30, 2014 and December 31, 2013, respectively, the Company had no cash equivalents.
	The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The cash balance at times may exceed federally insured limits, and at September 30, 2014 we had one bank account that exceeded the federally insured limit, and at December 31, 2013 we had two bank accounts that exceeded the federally insured limit.
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable represents trade obligations from customers that are subject to normal trade collection terms. The Company’s finance department monitors the status of customer receivables and takes actions to collect past due balances as necessary. The Company periodically evaluates the collectability of its accounts receivable and considers the need to establish an allowance for doubtful accounts based upon historical collection experience and specific customer information. Accordingly, the actual amounts could vary from the recorded allowances. There is also a review of customer discounts at the period end and an accrual made for discounts earned but not yet utilized by period end.
	Management performs ongoing evaluations of the Company’s customers’ financial condition and generally does not require collateral. Some international customers are required to pay for their orders in advance of shipment. Management reviews accounts receivable quarterly and reduces the carrying amount by a valuation allowance that reflects management’s best estimate of amounts that may not be collectible. Allowances, if any, for uncollectible accounts receivable are determined based upon the aging of accounts receivable, changes in customer credit worthiness, general market and economic conditions, and historical experience. Bad debt expense recognized as a result of our valuation allowance is classified under selling, general and administrative expense in the Consolidated Statement of Operations.  If receivable amounts are ultimately deemed to be uncollectible, the Company writes off the receivable balance against the valuation allowance.
	The Company does not charge interest on past due receivables. Receivables are determined to be past due based on the payment terms of the original invoices.
Inventory	'
	Inventory
	Inventory is valued at the lower of cost or market value. The cost of product inventory for MusclePharm and MusclePharm Canada is computed using actual cost on a First-In First-Out basis, and the cost of inventory for Biozone Labs is computed using an average cost basis. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, and estimates are made for obsolescence, excess or slow-moving inventories, non-conforming inventories, and expired inventory.
Prepaid Giveaways	'
	Prepaid Giveaways
	Prepaid giveaways represent non-inventory samples, which are given away to aid in promotion of the brand and products.
Prepaid Sponsorship and Endorsement Fees	'
	Prepaid Sponsorship and Endorsement Fees
	Prepaid sponsorship and endorsement fees represent fees paid in connection with Company sponsorships of certain events and trade shows as well as prepaid athlete endorsement fees, which are expensed over the period the fees are earned. A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts. Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions. Generally, endorsement and sponsorship payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract. Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the performance period for which the prepayment applies.
Prepaid Stock Compensation	'
	Prepaid Stock Compensation
	Prepaid stock compensation represents amounts paid with stock for future contractual benefits to be received. The Company amortizes these contractual benefits over the life of the contracts using the straight-line method.
Prepaid Expenses	'
	Prepaid Expenses
	Prepaid expenses consist of various payments that the Company has made in advance for goods or services to be received in the future. These prepaid expenses include legal retainers, print advertising, insurance and service contracts requiring up-front payments.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost and depreciated to their estimated residual value over their estimated useful lives. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are relieved from the accounts and the resulting gains or losses are included in the Statements of Operations. Repairs and maintenance costs are expensed as incurred. Depreciation is provided using the straight-line method for all property and equipment. We review our property and equipment for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. An impairment loss is calculated by determining the difference between the carrying values and the estimated fair values of these assets. We did not consider any of our property and equipment to be impaired during the nine months ended September 30, 2014 or 2013.
Intangible Assets	'
	Intangible Assets
	Definite-lived intangible assets are amortized over their related useful lives, using a straight-line basis consistent with the underlying expected future cash flows related to the specific intangible asset. Costs to renew or extend the life of intangible assets are capitalized and amortized over the remaining useful life of the asset.  Intangible assets are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of impairment exist, an estimate of undiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset's carrying value and estimated fair value. Fair value is determined through various valuation techniques, including market and income approaches as considered necessary. See Note 17 for further disclosure of intangible assets.
Accrued Liabilities	'
	Accrued Liabilities
	Accrued liabilities consist of amounts estimated by management for future liability payments that relate to the current accounting period. Management reviews these estimates periodically to determine their reasonableness and fair presentation.
Debt	'
	Debt
	The Company defines short term debt as any debt payment due less than one year from the date of the financial statements. Long term debt is defined as any debt payment due more than one year from the date of the financial statements. Refer to Note 8 for further disclosure of debt liabilities.
Derivatives	'
	Derivatives
	Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in equity instruments and warrants granted, and measurement of their fair value. In determining the appropriate fair value, the Company uses Black-Scholes or lattice option-valuation models. In assessing the convertible equity instruments, management determines if the convertible equity instrument is conventional convertible equity and further if the beneficial conversion feature requires separate measurement.
	Once derivative instruments are determined, they are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value is recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using a Black-Scholes or lattice option-pricing model. Once a derivative liability ceases to exist any remaining fair value is reclassified to additional paid-in capital if redeemed or through earnings if forfeited or expired.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company measures assets and liabilities at fair value based on an expected exit price which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.
	The following are the hierarchical levels of inputs to measure fair value:
	x	Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
	x	Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	x	Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.
	The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
	The Company’s financial instruments consisted primarily of accounts receivable, accounts payable, accrued liabilities, notes payable, and debt. The Company’s notes payable and debt approximate fair value based upon current borrowing rates available to the Company for debt with similar maturities. The carrying amounts of the Company’s financial instruments generally approximated their fair values as of September 30, 2014 and December 31, 2013, respectively, due to the short-term nature of these instruments.
Stock-Based Compensation	'
	Stock-Based Compensation
	Generally, all forms of stock-based compensation, including stock option grants, warrants, restricted stock grants, and stock appreciation rights are measured at their fair value on the awards’ grant date, based on estimated number of awards that are ultimately expected to vest and expensed on a straight-line basis. Share-based compensation awards issued to non- employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based compensation, whichever is more readily determinable.
Revenue Recognition	'
	Revenue Recognition
	The Company derives revenue primarily from sale of products. The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) product has been shipped or delivered, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.
	Depending on individual customer agreements, sales are recognized either upon shipment of products to customers or upon delivery. For all Canadian sales, which represent 3% of total sales, recognition occurs upon shipment.
	The Company records sales allowances and discounts as a direct reduction of sales. The Company grants volume incentive rebates to certain customers based on contractually agreed upon percentages once certain thresholds have been met. These volume incentive rebates are recorded as a direct reduction to sales.
	The Company has determined that customer advertising related credits are accounted for based on the guidance of ASC No. 605-50-55 (“Revenue Recognition” – Customer Payments and Incentives), which indicates that, absent evidence of benefit to the vendor, appropriate treatment requires netting these types of payments against revenues and not expensing as advertising expense.
Advertising and Promotion	'
	Advertising and Promotion
	Advertising and promotion expenses include digital and print advertising, trade show events, athletic endorsements and sponsorships, and promotional giveaways. Advertising expenses are recognized in the month that the advertising appears while costs associated with trade show events are expensed when the event occurs. For major trade shows, the expenses are recognized within the calendar year over the period in which we recognize revenue associated with sales generated at the trade show. Costs related to promotional giveaways are expensed when the product is either given out at a promotional event or shipped to the customer.
	A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts. Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions. Generally, endorsement payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract. Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the period for which the prepayment applies.
	Some of the contracts provide for contingent payments to endorsers or athletes based upon specific achievement in their sports (e.g. winning a championship). The Company records expense for these payments when the endorser achieves the specific achievement.
Income Taxes	'
	Income Taxes
	Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Beginning with the adoption of Financial Accounting Standards Board (“FASB”) Interpretation No. 48, Accounting for Uncertainty in Income Taxes, (included in FASB ASC Subtopic 740-10, Income Taxes — Overall), the Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
	The Company records interest and penalties related to unrecognized tax benefits in income tax expense. There were no interest or penalties related to unrecognized tax benefits for the three and nine months ended September 30, 2014 and 2013.
Foreign Currency	'
	Foreign Currency
	MusclePharm began operations in Canada in April 2012. The Canadian Dollar was determined to be the functional currency as the majority of the transactions related to the day to day operations of the business are in Canadian Dollars. At the end of the period, the financial results of the Canadian operation are translated into the U.S. Dollar, which is the reporting currency, and added to the U.S. operations for consolidated company financial results. The revenue and expense items are translated using the average rate for the month and the assets and liabilities at the month end of rate. Transactions that have completed the accounting cycle and resulted in a gain or loss related to translation are recorded in realized gain or loss due to foreign currency translation under other income and expense on the income statement. Transactions that have not completed their accounting cycle but appear to have gain or loss due to the translation process are recorded as unrealized gain or loss due to translation and recorded as accumulated other comprehensive income (loss) in the equity section on the balance sheet until such date the accounting cycle of the transaction is complete and the actual realized gain or loss is recognized.

Composition_of_Certain_Financi1

Composition of Certain Financial Statement Captions (Tables)	9 Months Ended
	Sep. 30, 2014
Composition Of Certain Financial Statement Captions [Abstract]	'
Schedule of Accounts Receivable, Net of Allowance	'
	Accounts receivable, net of allowance consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Accounts receivable	$	24,224,380		$	14,830,487
	Less: allowance for discounts		(851,275	)		(1,060,000	)
	Less: allowance for doubtful accounts		(153,033	)		(29,307	)
	Accounts receivable - net	$	23,220,072		$	13,741,180
Schedule of Inventory	'
	Inventory, net consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Raw materials inventory	$	2,221,068		$	-
	Work in process inventory		59,533			-
	Finished goods inventory		21,746,542			15,772,368
	Inventory	$	24,027,143		$	15,772,368
Schedule of Prepaid Expense	'
	Prepaid expenses consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Prepaid advertising and promotion	$	855,963		$	760,740
	Prepaid professional services		195,368			74,730
	Prepaid insurance		164,089			280,878
	Prepaid software license fees		135,738			86,205
	Inventory deposit		131,413			-
	Prepaid rent		117,854			-
	Prepaid director fees		72,890			-
	Prepaid taxes		37,675			-
	Prepaid research & development fees		20,897			22,500
	Prepaid support agreements		13,500			3,499
	Prepaid license fees		-			90,623
	Prepaid - other		86,830			16,043
		$	1,832,217		$	1,335,218
Schedule of Other Current Assets	'
	Other current assets consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Volume rebate receivable	$	226,174		$	-
	Vendor credit		260,017			-
	Line of credit fees - net		80,664			-
	Credit card pre-payments		26,027			-
	Other current assets		44,542			40,805
		$	637,424		$	40,805
Schedule of Property, Plant and Equipment	'
	Property and equipment consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Furniture, fixtures and equipment	$	3,646,144		$	1,849,462
	Leasehold improvements		2,262,558			619,159
	Manufacturing and lab equipment		1,248,993			-
	Vehicles		444,065			442,300
	Displays		341,346			33,683
	Website		193,809			11,462
	Construction in process		1,433,081			1,018,509
	Total		9,569,996			3,974,575
	Less: Accumulated depreciation and amortization		(2,266,984	)		(1,360,991	)
		$	7,303,012		$	2,613,584
Schedule of Other Assets	'
	Other assets consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Security deposit	$	108,394		$	85,419
	Prepaid advertising and promotion - long term		155,139			58,810
	Other		7,049			-
		$	270,582		$	144,229
Schedule of Accrued Liabilities	'
	Accrued liabilities consisted of the following at September 30, 2014 and December 31, 2013:
		As of			As of
		30-Sep-14			31-Dec-13
	Accrued payables	$	2,603,001		$	1,044,520
	Employee compensation and benefits		2,235,759			1,137,681
	Accrued taxes		6,430			71,771
	Other		49,160			63,929
		$	4,894,350		$	2,317,901
Schedule of Sales	'
	Sales for the three and nine months ended September 30, 2014 and 2013 were as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Sales	$	55,634,539		$	31,080,225		$	164,168,386		$	84,519,744
	Discounts and returns		(7,866,219	)		(5,736,257	)		(19,450,625	)		(11,134,551	)
	Sales - Net	$	47,768,320		$	25,343,968		$	144,717,761		$	73,385,193
	Discounts and returns as a percent of gross sales		14	%		18	%		12	%		13	%

Concentrations_Tables

Concentrations (Tables)	9 Months Ended
	Sep. 30, 2014
Accounts Receivable [Member]	'
Concentration Risk [Line Items]	'
Schedules of Concentration of Risk, by Risk Factor	'
	At September 30, 2014 and December 31, 2013, the Company had the following concentrations of accounts receivable:
	Customer		As of September 30, 2014			As of December 31, 2013
	Bodybuilding.com			16	%		14	%
	B			10	%	*		%
	C			10	%	*		%
	D		*		%		24	%
	E		*		%		16	%
	*	Less than 10% of total accounts receivable
Sales Revenue, Net [Member]	'
Concentration Risk [Line Items]	'
Schedules of Concentration of Risk, by Risk Factor	'
	The Company had the following concentrations of revenues:
			Three Months Ended September 30,
	Customer		2014			2013
	Bodybuilding.com			14	%		32	%
	B			10	%	*		%
	C		*		%		10	%
			Nine Months Ended September 30,
	Customer		2014			2013
	Bodybuilding.com			14	%		30	%
	B		*		%	*		%
	C		*		%		11	%
	*	Less than 10% of gross sales
Cost of Goods, Total [Member]	'
Concentration Risk [Line Items]	'
Schedules of Concentration of Risk, by Risk Factor	'
	The Company had the following concentration of purchases with contract manufacturers:
			Three Months Ended September 30,
	Vendor		2014			2013
	A			58%			27%
	B			36%			72%
			Nine Months Ended September 30,
	Vendor		2014			2013
	A			51%			22%
	B			45%			78%

Financial_Instruments_Tables

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Summary of Financial Assets and Liabilities	'
	The following is a summary of financial assets and liabilities:
		As of September 30,		As of December 31,
		2014		2013
	Assets
	Debt securities - FUSE convertible notes (Level 2)	$	-	$	259,715
	Derivative instruments - FUSE warrants (Level 2)		-		119,248
			-		378,963
	Liabilities
	Derivative liabilities  - Series D shares (Level 2)	$	-	$	1,147,330

Investment_in_Debt_Securities_

Investment in Debt Securities (Tables)	9 Months Ended
	Sep. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Summary of Marketable Debt Security Activity	'
	The following summarizes the Company’s marketable securities activity for the year ended December 31, 2013:
		Convertible
		Note
	FV of debt security on August 26, 2013	$	1,955,462
	Premium on purchase date		44,538
	Discount for value of derivative instrument		-1,248,292
	Accretion of net discount		1,248,292
	Conversion of principal		-1,000,000
	Repayments received		-1,000,000
	Balance – December 31, 2013	$	-

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Long Term Debt	'
	Debt consists of the following:
		As of September 30,			As of December 31,
		2014			2013
	Revolving line of credit	$	8,000,000		$	2,500,000
	Notes payable		45,600			59,600
	Auto loan - secured		-			2,902
	Total debt		8,045,600			2,562,502
	Less: current portion		(8,045,600	)		(2,562,502	)
	Long term debt	$	-		$	-
Schedule of Revolving Lines of Credit Activity	'
	Lines of credit consisted of the following activity:
		ANB Bank			US Bank
	Balance - December 31, 2013	$	-		$	2,500,000
	Borrowing		8,000,000			-
	Principal repayments		-			(2,500,000	)
	Balance - September 30, 2014	$	8,000,000		$	-
Schedule of Notes Payable Activity	'
	Notes payable consisted of the following activity:
	Balance - December 31, 2013	$	59,600
	Principal repayments		(14,000	)
	Balance - September 30, 2014	$	45,600
Schedule of Vehicle Loan Activity and Terms	'
	Vehicle loan account consisted of the following activity and terms:
	Balance - December 31, 2013	$	2,902
	Principal repayments		(2,902	)
	Balance - September 30, 2014	$	-

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Schedule of Fair Value of Derivative Instruments Conversion Feature	'
	The fair value of the conversion feature is summarized as follows:
	Derivative liability - December 31, 2013	$	1,147,330
	Fair value mark to market adjustment for equity instruments		(373,944	)
	Conversion instruments exercise		(773,386	)
	Derivative liability - September 30, 2014	$	-

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Stockholders Equity Note [Abstract]	'
Schedule of Stockholders Equity	'
	During the nine months ended September 30, 2014, the Company issued the following common stock:
			Shares				Value				Range of Value
											per Share
	Transaction Type										($)
	Conversion of Series D preferred stock to common stock			263,000			$	773,517				2.94
	Executive/Board of Director compensation			66,878				315,991			3.48 - 8.70
	Stock issued for services			476,853				5,402,300			11.19 - 13.41
	Stock issued for Biozone Labs acquisition			1,200,000				9,840,000				8.2
	Total			2,006,731			$	16,331,808			2.94 - 13.41
Schedule of Common Stock Equivalents	'
	The Company has the following common stock equivalents as of September 30, 2014 and 2013, respectively:
		As of September 30,
		2014				2013
	Stock options (exercise price - $425/share)		472				472
	Warrants (exercise price - $4 /share)		-				288,000
	Warrants (exercise price - $1,275/share)		89				89
	Warrants (exercise price - $11.90/share)		100,000				-
	Unvested restricted stock		1,495,117				1,647,581
	Total common stock equivalents		1,595,678				1,936,142
Schedule of Earnings Per Share, Basic and Diluted	'
	The following is a reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the three and nine months ended September 30, 2014 and 2013, respectively:
		Three months ended								Nine months ended
		September 30,								September 30,
		2014				2013				2014				2013
	Net income (loss)	$	602,618			$	(3,945,836	)		$	2,404,338			$	(13,729,627	)
	Weighted average number of common shares		11,032,996				8,475,084				10,652,781				6,626,125
	outstanding
	Incremental shares from the assumed exercise of		1,579,900				-				1,459,236				-
	dilutive agreements
	Diluted common shares outstanding		12,612,896				8,475,084				12,112,017				6,626,125
	Earnings (loss) per shares - basic	$	0.05			$	(0.47	)		$	0.23			$	(2.07	)
	Earnings (loss) per shares - diluted	$	0.05			$	(0.47	)		$	0.2			$	(2.07	)
Schedule of Warrants Activity	'
	A summary of warrant activity for the Company for the nine months ended September 30, 2014 is as follows:
			Number of Warrants				Weighted Average
							Exercise Price
	Outstanding - December 31, 2013			263,089			$	4.43
	Granted			100,000				11.9
	Exercised			(263,000	)			4
	Balance as September 30, 2014			100,089			$	13.02
	Warrants Outstanding																Warrants Exercisable
	Range of				Number				Weighted Average				Weighted Average				Number		Weighted		Intrinsic Value
	Exercise Prices				Outstanding				Remaining				Exercise Price				Exercisable		Average
									Contractual Life (in										Exercise Price
									years)
	$	11.9				100,000				4.79			$	11.9				8,336	$	11.9	$	130,000
		1,275.00				89				0.79				1,275.00				89		1,275.00		-

Commitments_Contingencies_and_1

Commitments, Contingencies and Other Matters (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases	'
	As of September 30, 2014, future minimum lease payments are as follows:
	Years Ending December 31,
	2014 (remaining 3 months)	$	309,727
	2015		1,105,030
	2016		898,311
	2017		841,118
	2018		838,246
	Thereafter		3,519,391
	Total minimum lease payments	$	7,511,823
Schedule of Future Minimum Lease Payments for Capital Leases	'
	As of September 30, 2014, future minimum lease payments are as follows:
	Years Ending December 31,
	2014 (remaining 3 months)	$	28,300
	2015		114,254
	2016		101,553
	2017		19,352
	Total minimum lease payments		263,459
	Less amounts representing interest		(29,846	)
	Present value of minimum lease payments	$	233,613
Contractual Obligation, Fiscal Year Maturity Schedule	'
	The total outstanding payments are as follows:
	Outstanding Payments	2014			2015		2016		2017		2018		Total
	Endorsement	$	1,864,000		$	8,354,934	$	6,526,833	$	6,600,000	$	3,500,000	$	26,845,767
	Sponsorship		1,153,750			4,905,000		1,137,500		100,000		-		7,296,250
	Total	$	3,017,750		$	13,259,934	$	7,664,333	$	6,700,000	$	3,500,000	$	34,142,017

Biozone_Labs_Acquisition_Table

Biozone Labs Acquisition (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Schedule of Purchase Price Allocation	'
	Based upon the fair values, the purchase price allocation is as follows:
	Purchase Price Allocation
	Net Tangible Assets
	Current assets	$	3,183,152
	Property & equipment		1,859,066
	Liabilities assumed		(1,378,920	)
	Total net tangible assets acquired		3,663,298
	Identified Intangible Assets
	Customer relationships		3,130,000
	Technology		2,158,000
	Brand		1,776,000
	Non-compete agreements		69,000
	Total identified intangible assets acquired		7,133,000
	Bargain Purchase Gain		(3,685,568	)
	Total	$	7,110,730
Schedule of Business Acquisition, Pro Forma Information	'
	The unaudited pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on January 1, 2013 for the three and nine months ended September 30, 2013 is as follows:
	Three Months Ended September 30, 2013
		MusclePharm			BioZone			Combined			Pro Forma				MusclePharm
		Corp.			Pharmaceuticals			Before Pro			Adjustments				Corp.
					Inc.			Forma							Pro Forma
								Adjustments
	Sales - net	$	25,343,968		$	2,086,985		$	27,430,953		$	-			$	27,430,953
	Net loss		(3,945,836	)		1,625,451			(2,320,385	)		(70,144	)	(a)		(2,390,529	)
	Net loss per share - basic and diluted	$	(0.49	)		-			-			-			$	(0.29	)
	Weighted average number of		8,125,084			-			-			-				8,125,084
	common shares used in per share
	calculations - basic and diluted
	Nine Months Ended September 30, 2013
								Combined
					BioZone			Before Pro							MusclePharm
		MusclePharm			Pharmaceuticals			Forma			Pro Forma				Corp.
		Corp.			Inc.			Adjustments			Adjustments				Pro Forma
	Sales - net	$	73,385,193		$	5,764,116		$	79,149,309		$	-			$	79,149,309
	Net loss		(13,729,627	)		(194,900	)		(13,924,527	)		(218,162	)	(a)		(14,142,689	)
	Net loss per share - basic and diluted	$	(2.19	)		-			-			-			$	(2.25	)
	Weighted average number of		6,276,125			-			-			-				6,276,125
	common shares used in per share
	calculations - basic and diluted
	(a)Pro forma adjustment to eliminate historical seller depreciation expense and record depreciation and amortization expense resulting from the assets acquired.

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets	'
	Intangible assets consist of the following:
									Weighted
		As of September 30, 2014							average
				Accumulated					amortization
		Gross Assets		Amortization			Net Assets		period (years)
	Amortized intangible assets
	Customer relationships	$	3,130,000	$	(156,500	)	$	2,973,500		14.26
	Technology		2,158,000		(202,313	)		1,955,687		7.26
	Non-compete agreements		69,000		(25,875	)		43,125		1.25
	Patents		52,501		(19,596	)		32,905		2.77
	Trademarks		35,000		(17,818	)		17,182		2.25
	Brand		1,776,000		-			1,776,000		19.27
	Domain name		67,665		-			67,665		-
	Total intangible assets		7,288,166		(422,102	)		6,866,064
Schedule of Estimated Future Amortization Expense of Intangible Assets	'
	As of September 30, 2014, the estimated future amortization expense of intangible assets is as follows:
	2014 (remaining 3 months)	$	222,349
	2015		622,061
	2016		584,083
	2017		571,497
	2018		569,491
	Thereafter		4,296,583
	Total amortization expense	$	6,866,064

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Accounting Policies [Line Items]	'	'	'	'	'
Cash Equivalents	$0	'	$0	'	$0
Recognized Income Tax Positions Percentage	'	'	50.00%	'	'
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	$0	$0	$0	$0	'
Canadian Sales [Member]	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'
Concentration Risk, Percentage	'	'	3.00%	'	'

Composition_of_Certain_Financi2

Composition of Certain Financial Statement Captions - Schedule of Accounts Receivable, Net of Allowance (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Receivables Net Current [Abstract]	'	'
Accounts receivable	$24,224,380	$14,830,487
Less: allowance for discounts	-851,275	-1,060,000
Less: allowance for doubtful accounts	-153,033	-29,307
Accounts receivable - net	$23,220,072	$13,741,180

Composition_of_Certain_Financi3

Composition of Certain Financial Statement Captions - Schedule of Inventory (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventory Net [Abstract]	'	'
Raw materials inventory	$2,221,068	'
Work in process inventory	59,533	'
Finished goods inventory	21,746,542	15,772,368
Inventory	$24,027,143	$15,772,368

Composition_of_Certain_Financi4

Composition of Certain Financial Statement Captions - Schedule of Prepaid Expense (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Prepaid Expense Current [Abstract]	'	'
Prepaid advertising and promotion	$855,963	$760,740
Prepaid professional services	195,368	74,730
Prepaid insurance	164,089	280,878
Prepaid software license fees	135,738	86,205
Inventory deposit	131,413	'
Prepaid rent	117,854	'
Prepaid director fees	72,890	'
Prepaid taxes	37,675	'
Prepaid research & development fees	20,897	22,500
Prepaid support agreements	13,500	3,499
Prepaid license fees	'	90,623
Prepaid - other	86,830	16,043
Prepaid Expense, Current	$1,832,217	$1,335,218

Composition_of_Certain_Financi5

Composition of Certain Financial Statement Captions - Schedule of Other Current Assets (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Composition Of Certain Financial Statement Captions [Abstract]	'	'
Volume rebate receivable	$226,174	'
Vendor credit	260,017	'
Line of credit fees - net	80,664	'
Credit card pre-payments	26,027	'
Other current assets	44,542	40,805
Other Assets, Current	$637,424	$40,805

Composition_of_Certain_Financi6

Composition of Certain Financial Statement Captions - Schedule of Property, Plant and Equipment (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property Plant And Equipment [Line Items]	'	'
Total	$9,569,996	$3,974,575
Less: Accumulated depreciation and amortization	-2,266,984	-1,360,991
Property, Plant and Equipment, Net	7,303,012	2,613,584
Furniture, Fixtures And Equipment [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Total	3,646,144	1,849,462
Leasehold Improvements [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Total	2,262,558	619,159
Manufacturing and lab equipment [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Total	1,248,993	'
Vehicles [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Total	444,065	442,300
Displays [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Total	341,346	33,683
Website [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Total	193,809	11,462
Construction in Progress [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Total	$1,433,081	$1,018,509

Composition_of_Certain_Financi7

Composition of Certain Financial Statement Captions - Schedule of Other Assets (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Other Assets Noncurrent [Abstract]	'	'
Security deposit	$108,394	$85,419
Prepaid advertising and promotion - long term	155,139	58,810
Other	7,049	'
Other Assets, Noncurrent	$270,582	$144,229

Composition_of_Certain_Financi8

Composition of Certain Financial Statement Captions - Schedule of Accrued Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accrued Liabilities Current [Abstract]	'	'
Accrued payables	$2,603,001	$1,044,520
Employee compensation and benefits	2,235,759	1,137,681
Accrued taxes	6,430	71,771
Other	49,160	63,929
Accrued Liabilities, Current	$4,894,350	$2,317,901

Composition_of_Certain_Financi9

Composition of Certain Financial Statement Captions - Schedule of Sales (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Sales Revenue Goods Net [Abstract]	'	'	'	'
Sales	$55,634,539	$31,080,225	$164,168,386	$84,519,744
Discounts and returns	-7,866,219	-5,736,257	-19,450,625	-11,134,551
Sales - Net	$47,768,320	$25,343,968	$144,717,761	$73,385,193
Discounts and returns as a percent of gross sales	14.00%	18.00%	12.00%	13.00%

Concentrations_Schedules_of_Co

Concentrations - Schedules of Concentration of Risk, by Risk Factor (Details)

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Cost of Goods, Total [Member]

Cost of Goods, Total [Member]

Cost of Goods, Total [Member]

Cost of Goods, Total [Member]

Cost of Goods, Total [Member]

Cost of Goods, Total [Member]

Cost of Goods, Total [Member]

Cost of Goods, Total [Member]

Bodybuilding.com [Member]

Bodybuilding.com [Member]

Customer B [Member]

Customer C [Member]

Customer D [Member]

Customer E [Member]

Bodybuilding.com [Member]

Bodybuilding.com [Member]

Bodybuilding.com [Member]

Bodybuilding.com [Member]

Customer B [Member]

Customer B [Member]

Customer B [Member]

Customer C [Member]

Customer C [Member]

Vendor A [Member]

Vendor A [Member]

Vendor A [Member]

Vendor A [Member]

vendor B [Member]

vendor B [Member]

vendor B [Member]

vendor B [Member]

Concentration Risk [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration Risk, Percentage

16.00%

14.00%

10.00%

10.00%

24.00%

16.00%

14.00%

32.00%

14.00%

30.00%

10.00%

'

[1]

'

[1]

10.00%

11.00%

58.00%

27.00%

51.00%

22.00%

36.00%

72.00%

45.00%

78.00%

[1]

Less than 10% of gross sales

Financial_Instruments_Summary_

Financial Instruments - Summary of Financial Assets and Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Assets	'	'
Debt securities - FUSE convertible notes (Level 2)	'	$259,715
Derivative instruments - FUSE warrants (Level 2)	'	119,248
Assets, Fair Value Disclosure, Total	'	378,963
Liabilities	'	'
Derivative liabilities - Series D shares (Level 2)	$0	$1,147,330

Financial_Instruments_Addition

Financial Instruments - Additional Information (Details) (USD $)	0 Months Ended
	Apr. 02, 2014
Fair Value Disclosures [Abstract]	'
Sale Of Convertible Notes And Warrants	$215,000

Investment_in_Debt_Securities_1

Investment in Debt Securities - Additional Information (Details) (USD $)	0 Months Ended	4 Months Ended
	Aug. 26, 2013	Dec. 31, 2013	Sep. 30, 2014
Debt Instrument [Line Items]	'	'	'
Investment in debt securities	'	$259,715	'
Convertible Note [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Purchase of secured convertible promissory note	2,000,000	'	'
Investment in debt securities	1,955,462	'	0
Marketable securities premium on purchase date	'	44,538	'
Discount for value of derivative instrument	'	$1,248,292	'
Convertible Note [Member] | secured convertible promissory note [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Debt Instrument, Maturity Term	'1 year	'	'
Debt Instrument, Interest Rate, Stated Percentage	10.00%	'	'
Debt Conversion, Converted Instrument, Shares Issued	10,000,000	'	'
Debt Instrument, Convertible, Conversion Price	$0.20	'	'
Restriction on beneficial ownership limitation, Percentage of common stock outstanding upon conversion.	4.99%	'	'

Investment_in_Debt_Securities_2

Investment in Debt Securities - Summary of Marketable Debt Security Activity (Details) (USD $)	4 Months Ended
	Dec. 31, 2013	Sep. 30, 2014
Convertible Note [Member]	'	'
Schedule Of Available For Sale Securities [Line Items]	'	'
FV of debt security on August 26, 2013	$1,955,462	$0
Premium on purchase date	44,538	'
Discount for value of derivative instrument	-1,248,292	'
Accretion of net discount	1,248,292	'
Conversion of principal	-1,000,000	'
Repayments received	-1,000,000	'
Balance b December 31, 2013	$0	'

Derivative_Instrument_Addition

Derivative Instrument - Additional Information (Details) (Biozone Warrants [Member], USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Derivatives Fair Value [Line Items]	'	'
Payments to Acquire Trading Securities Held-for-investment	'	$1,248,292
Equity Method Investment, Ownership Percentage	4.99%	'
Fair Value Assumptions, Weighted Average Volatility Rate	70.00%	'
secured convertible promissory note [Member]	'	'
Derivatives Fair Value [Line Items]	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	10,000,000
Investment Warrants, Exercise Price	'	$0.40
Warrants Expiration Term	'	'10 years

Debt_Schedule_of_Long_Term_Deb

Debt - Schedule of Long Term Debt (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]	'	'
Revolving line of credit	$8,000,000	$2,500,000
Notes payable	45,600	59,600
Auto loan - secured	0	2,902
Total debt	8,045,600	2,562,502
Less: current portion	-8,045,600	-2,562,502
Long term debt	$0	$0

Debt_Schedule_of_Revolving_Lin

Debt - Schedule of Revolving Lines of Credit Activity (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Debt Instrument [Line Items]	'	'
Balance - December 31, 2013	$2,500,000	'
Borrowing	8,000,000	0
Balance - September 30, 2014	8,000,000	'
American National Bank [Member]	'	'
Debt Instrument [Line Items]	'	'
Borrowing	8,000,000	'
Balance - September 30, 2014	8,000,000	'
US Bank [Member]	'	'
Debt Instrument [Line Items]	'	'
Balance - December 31, 2013	2,500,000	'
Principal repayments	($2,500,000)	'

Debt_Additional_Information_De

Debt - Additional Information (Details) (USD $)	0 Months Ended	9 Months Ended		3 Months Ended	12 Months Ended		0 Months Ended
	Dec. 24, 2013	Sep. 30, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Dec. 24, 2013	Sep. 12, 2014	Sep. 12, 2014	Sep. 12, 2014
				Notes Payable, Other Payables [Member]	Notes Payable, Other Payables [Member]	U.S. Bank, N.A D Savings Deposits [Member]	American National Bank [Member]	Maximum [Member]	Minimum [Member]
								American National Bank [Member]	American National Bank [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Line of Credit Facility, Expiration Date	15-Sep-14	'	'	'	'	'	12-Sep-17	'	'
Line of Credit Facility, Interest Rate Description	'the prime rate plus 2%	'	'	'	'	'	'prime rate plus 2%	'	'
Line of Credit Facility, Maximum Borrowing Capacity	$2,500,000	'	'	'	'	'	$8,000,000	'	'
Debt Instrument, Interest Rate During Period	'	'	'	'	6.99%	'	5.25%	'	'
Debt Issuance Costs	'	'	'	'	'	'	81,800	'	'
Debt Instrument, Restrictive Covenants	'	'In addition, the facility requires compliance by the Company with the following covenants: during each quarter the outstanding principal balance of the line of credit must be reduced and maintained below $3,000,000 for a minimum of 14 non-consecutive days, without prior written consent, the Company cannot incur additional debt obligations during any 12-month period that, in the aggregate, exceeds $250,000, or any individual debt obligation that exceeds $100,000, maintain a minimum market capitalization of $65,000,000, without prior written consent, the Company cannot enter any cash transaction, other than in the ordinary course of business, in excess of $1,000,000, for each calendar quarter, maintain quarterly average balance in excess of $1,200,000, maintain a debt service coverage ratio of at least 2.0:1, and maintain a current ratio of at least 1.5:1.	'	'	'	'	'	'	'
Debt Instrument, Covenant Compliance	'	'The Company was in compliance with these covenants as of September 30, 2014.	'	'	'	'	'	'	'
Line of Credit Facility, Principal Outstanding	'	'	'	'	'	'	'	3,000,000	'
Aggregate Debt Obligations	'	'	'	'	'	'	250,000	'	'
Individual Debt Obligation	'	'	'	'	'	'	100,000	'	'
Market Capitalization	'	'	'	'	'	'	65,000,000	'	'
Maximum Cash Transaction without Prior Consent From Lender	'	'	'	'	'	'	1,000,000	'	'
Compensating Balance, Amount	'	'	'	'	'	'	'	'	1,200,000
Debt Service Coverage Ratio	'	'	'	'	'	'	200.00%	'	'
Current Ratio	'	'	'	'	'	'	150.00%	'	'
Restricted Cash and Investments, Current, Total	'	'	'	'	'	2,500,000	'	'	'
Debt Default, Short-term Debt, Amount	'	45,600	59,600	'	'	'	'	'	'
Debt Instrument, Periodic Payment	'	'	'	$1,008	'	'	'	'	'

Debt_Schedule_of_Notes_Payable

Debt - Schedule of Notes Payable Activity (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Balance - December 31, 2013	$59,600
Principal repayments	-14,000
Balance - September 30, 2014	$45,600

Debt_Schedule_of_Vehicle_Loan_

Debt - Schedule of Vehicle Loan Activity and Terms (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Balance - December 31, 2013	$2,902
Principal repayments	-2,902
Balance - September 30, 2014	$0

Derivative_Liabilities_Schedul

Derivative Liabilities - Schedule of Fair Value of Derivative Instruments Conversion Feature (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'	'
Derivative liability - December 31, 2013	$1,147,330	'
Fair value mark to market adjustment for equity instruments	-373,944	'
Conversion instruments exercise	-773,386	-11,688,463
Derivative liability - September 30, 2014	$0	'

Derivative_Liabilities_Additio

Derivative Liabilities - Additional Information (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Apr. 02, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'	'	'
Derivative expense	$0	$96,913	'
Embedded Derivative, Fair Value of Embedded Derivative Liability	'	'	$773,254

Restricted_Stock_Additional_In

Restricted Stock - Additional Information (Details) (USD $)

9 Months Ended

0 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

6-May-14

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Nov. 30, 2012

Sep. 30, 2014

Dec. 31, 2012

Jun. 30, 2013

Sep. 30, 2014

Mar. 17, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 01, 2014

Sep. 30, 2014

June 2013 Employee Stock Grant Plan [Member]

June 2013 Employee Stock Grant Plan [Member]

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Scenario, Forecast

Scenario, Forecast

December 31, 2013 [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

key employees officers and directors [Member]

key employees officers and directors [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

June 2013 Employee Stock Grant Plan [Member]

Restricted Stock

Restricted Stock

December 31, 2015 [Member]

December 31, 2015 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued For Services (in shares)

476,853

'

'

'

'

'

'

'

'

'

129,413

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued For Services

$5,402,300

'

'

'

'

'

'

'

'

'

$449,900

'

'

'

'

'

'

'

'

'

'

'

Shares Vesting In Next Twelve Months Number

'

'

'

'

'

'

'

'

'

'

'

'

43,137

'

'

'

'

'

'

'

'

'

Shares Vesting In Year Two Number

'

'

'

'

'

'

'

'

43,138

'

'

'

'

'

'

'

'

'

'

'

43,138

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

'

'

'

'

'

'

'

'

'

'

'

86,275

'

'

263,500

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized

'

'

'

'

'

'

'

'

'

'

'

37,800

'

'

'

'

80,220

'

88,658

995,400

'

'

Number of restricted stock award authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

1,550,000

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Restricted Stock Award, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

17,065,500

'

320,007

'

152,000

'

'

'

'

Number of restricted stock awards expected to vest

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,200

'

'

'

'

'

'

'

'

Restricted stock awards expected to vest, fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

16,517,202

'

'

'

'

'

'

'

'

Restricted stock agreement grant vesting percentage

'

'

'

'

'

'

'

'

'

17.00%

'

'

'

'

'

'

'

'

'

'

'

83.00%

Unamortized portion of vested awards

'

'

'

'

'

'

7,310,640

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Restricted Stock Award, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

48,856

'

19,364

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

16,284

'

6,456

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

100,000

'

120,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Granted, Value, Share-based Compensation, Gross

'

'

'

'

'

'

1,137,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

$6,942,357

$1,588,067

'

'

$2,317,818

$1,513,701

$6,837,585

$1,588,068

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Stockholders Equity (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Class Of Stock [Line Items]	'
Conversion of Series D preferred stock to common stock, Quantity	263,000
Executive/Board of Director compensation, Quantity	66,878
Stock issued for service, Quantity	476,853
Stock issued for Biozone Labs acquisition, Quantity	1,200,000
Total, Quantity	2,006,731
Conversion of Series D preferred stock to common stock, Valuation	$773,517
Executive/Board of Director compensation, Valuation	315,991
Stock issued for services, Valuation	5,402,300
Stock issued for Biozone Labs acquisition, Valuation	9,840,000
Total, Valuation	$16,331,808
Conversion of Series D preferred stock to common stock, Range Of value per share	$2.94
Stock issued for Biozone Labs acquisition, Range of value per share	$8.20
Minimum [Member]	'
Class Of Stock [Line Items]	'
Executive/Board of Director compensation, Range of Value per share	$3.48
Stock issued for services, Range of Value per share	$11.19
Total, Range of Value per Share	$2.94
Maximum [Member]	'
Class Of Stock [Line Items]	'
Executive/Board of Director compensation, Range of Value per share	$8.70
Stock issued for services, Range of Value per share	$13.41
Total, Range of Value per Share	$13.41

Stockholders_Equity_Schedule_o1

Stockholders' Equity - Schedule of Common Stock Equivalents (Details)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Class Of Stock [Line Items]	'	'
Total common stock equivalents	1,595,678	1,936,142
Stock Options (Exercise Price - $425/Share) [Member]	'	'
Class Of Stock [Line Items]	'	'
Total common stock equivalents	472	472
Unvested Restricted Stock [Member]	'	'
Class Of Stock [Line Items]	'	'
Total common stock equivalents	1,495,117	1,647,581
Warrants (Exercise Price - $4 /Share) [Member]	'	'
Class Of Stock [Line Items]	'	'
Total common stock equivalents	'	288,000
Warrants (Exercise Price - $1,275/Share) [Member]	'	'
Class Of Stock [Line Items]	'	'
Total common stock equivalents	89	89
Warrants (Exercise Price - $11.90/Share) [Member]	'	'
Class Of Stock [Line Items]	'	'
Total common stock equivalents	100,000	'

Stockholders_Equity_Schedule_o2

Stockholders' Equity - Schedule of Common Stock Equivalents (Parenthical) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Employee Stock Option [Member]	'	'
Class Of Stock [Line Items]	'	'
Exercise price per share	$425	$425
Warrant [Member]	'	'
Class Of Stock [Line Items]	'	'
Exercise price per share	$4	$4
Warrants One [Member]	'	'
Class Of Stock [Line Items]	'	'
Exercise price per share	$1,275	$1,275
Warrants Two [Member]	'	'
Class Of Stock [Line Items]	'	'
Exercise price per share	$11.90	$11.90

Stockholders_Equity_Schedule_o3

Stockholders' Equity - Schedule of Earnings Per Share, Basic and Diluted (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stockholders Equity Note [Abstract]	'	'	'	'
Net income (loss)	$602,618	($3,945,836)	$2,404,338	($13,729,627)
Weighted average number of common shares outstanding	11,032,996	8,475,084	10,652,781	6,626,125
Incremental shares from the assumed exercise of dilutive agreements	1,579,900	0	1,459,236	0
Diluted common shares outstanding	12,612,896	8,475,084	12,112,017	6,626,125
Earnings (loss) per shares - basic	$0.05	($0.47)	$0.23	($2.07)
Earnings (loss) per shares - diluted	$0.05	($0.47)	$0.20	($2.07)

Stockholders_Equity_Additonal_

Stockholders' Equity - Additonal Information (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013
					Escrow [Member]	Maximum [Member]
						Board of Directors Chairman [Member]
Stockholders Equity Disclosure [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	0	198	0	1,375	'	'
Stock Repurchased During Period, Shares	'	'	100,000	'	350,000	'
Stock Repurchased During Period, Value	'	'	$1,362,881	'	'	'
Stock Repurchased During Period Per Share	'	'	$13.63	'	'	'
Stock Repurchased Maximum Value	'	'	'	'	'	$5,000,000

Stockholders_Equity_Schedule_o4

Stockholders' Equity - Schedule of Warrants Activity (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Jul. 15, 2014
Class Of Stock [Line Items]	'	'
Number of Warrants, Outstanding Beginning Balance	263,089	'
Number of Warrants, Granted	100,000	'
Number of Warrants, Exercised	-263,000	'
Number of Warrants, Outstanding Ending Balance	100,089	'
Weighted Average Exercise Price, Beginning Balance	$4.43	'
Weighted Average Exercise Price, Granted	$11.90	'
Weighted Average Exercise Price, Exercised	$4	'
Weighted Average Exercise Price, Ending Balance	$13.02	'
Weighted Average Exercise Price, Balance (in dollars per share)	'	$11.90
Warrant [Member]	'	'
Class Of Stock [Line Items]	'	'
Warrants Exercisable, Intrinsic Value	$130,000	'
Warrant [Member] | Minimum [Member]	'	'
Class Of Stock [Line Items]	'	'
Weighted Average Exercise Price, Balance (in dollars per share)	$11.90	'
Warrant Outstanding Number Outstanding	89	'
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	'9 months 15 days	'
Warrant Outstanding Weighted Average Exercise Price	$11.90	'
Warrants Exercisable, Numbers Exercisable (in shares)	89	'
Warrants Exercisable, Weighted Average Exercise Price (in dollars per share)	$11.90	'
Warrant [Member] | Maximum [Member]	'	'
Class Of Stock [Line Items]	'	'
Weighted Average Exercise Price, Balance (in dollars per share)	$1,275	'
Warrant Outstanding Number Outstanding	100,000	'
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	'4 years 9 months 15 days	'
Warrant Outstanding Weighted Average Exercise Price	$1,275	'
Warrants Exercisable, Numbers Exercisable (in shares)	8,336	'
Warrants Exercisable, Weighted Average Exercise Price (in dollars per share)	$1,275	'

Commitments_Contingencies_and_2

Commitments, Contingencies and Other Matters - Additional Information (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Commitments And Contingency [Line Items]	'	'	'
Operating Lease Expire Term	'2029	'	'
Operating Leases, Rent Expense, Net	$988,550	$446,943	'
Capital lease - short term	97,925	'	26,653
Capital Lease Obligations, Noncurrent	135,689	'	54,639
Capital Leases, Balance Sheet, Assets by Major Class, Net, Total	295,778	'	'
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	22,619	'	'
Capital Lease Expire Term	'2017	'	'
Capital Lease Obligations	233,613	'	81,292
Product Liability Insurance Deduction	10,000	'	'
Aggregate Product Liability Retained Loss	20,000,000	'	'
Sponsorship and Endorsement Contract Liabilities [Member]	'	'	'
Commitments And Contingency [Line Items]	'	'	'
Lease expiration term	'2018	'	'
Contractual Obligation, Total	$34,142,017	'	'

Commitments_Contingencies_and_3

Commitments, Contingencies and Other Matters - Schedule of Future Minimum Rental Payments for Operating Leases (Details) (USD $)	Sep. 30, 2014
Years Ending December 31,	'
2014 (remaining 3 months)	$309,727
2015	1,105,030
2016	898,311
2017	841,118
2018	838,246
Thereafter	3,519,391
Total minimum lease payments	$7,511,823

Commitments_Contingencies_and_4

Commitments, Contingencies and Other Matters - Schedule of Future Minimum Lease Payments for Capital Leases (Details) (USD $)	Sep. 30, 2014
Years Ending December 31,	'
2014 (remaining 3 months)	$28,300
2015	114,254
2016	101,553
2017	19,352
Total minimum lease payments	263,459
Less amounts representing interest	-29,846
Present value of minimum lease payments	$233,613

Commitments_Contingencies_and_5

Commitments, Contingencies and Other Matters - Contractual Obligation, Fiscal Year Maturity Schedule (Details) (Sponsorship and Endorsement Contract Liabilities [Member], USD $)	Sep. 30, 2014
Contractual Obligation Fiscal Year Maturity [Line Items]	'
2014	$3,017,750
2015	13,259,934
2016	7,664,333
2017	6,700,000
2018	3,500,000
Contractual Obligation, Total	34,142,017
Endorsement [Member]	'
Contractual Obligation Fiscal Year Maturity [Line Items]	'
2014	1,864,000
2015	8,354,934
2016	6,526,833
2017	6,600,000
2018	3,500,000
Contractual Obligation, Total	26,845,767
Sponsorship [Member]	'
Contractual Obligation Fiscal Year Maturity [Line Items]	'
2014	1,153,750
2015	4,905,000
2016	1,137,500
2017	100,000
Contractual Obligation, Total	$7,296,250

Defined_Contribution_Plan_Addi

Defined Contribution Plan - Additional Information (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Compensation And Retirement Disclosure [Abstract]	'	'
Noncash Contribution Expense	$17,500	'
Defined Contribution Plan, Employer Discretionary Contribution Amount	$220,505	$44,940

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Details) (USD $)

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Oct. 16, 2013

Bodybuilding.com [Member]

Bodybuilding.com [Member]

Bodybuilding.com [Member]

Bodybuilding.com [Member]

Bodybuilding.com [Member]

VP and General Manager [Member]

VP and General Manager [Member]

VP and General Manager [Member]

VP and General Manager [Member]

Frost Real Estate Holdings, LLC [Member]

Frost Real Estate Holdings, LLC [Member]

Frost Real Estate Holdings, LLC [Member]

sqft

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from Related Parties

'

'

$7,852,060

$9,694,910

$23,352,058

$24,648,755

'

'

'

'

'

'

'

'

Due from Related Parties

'

'

3,775,939

'

3,775,939

'

2,051,265

'

'

'

'

'

'

'

Purchase of marketing services

'

'

349,999

'

1,038,884

'

'

'

'

'

'

'

'

'

Operating Leases, Rent Expense, Net

$988,550

$446,943

'

'

'

'

'

$22,948

$18,886

$63,962

$57,857

$14,358

$41,186

'

Lease Expiration Date

31-Mar-16

'

'

'

'

'

'

'

'

'

'

'

'

'

Area of Land

'

'

'

'

'

'

'

'

'

'

'

'

'

1,437

Term of Lease

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease, Renewal Term

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Compensation Arrangements, Overall, Description

'the Company purchased split dollar life insurance policies on certain key executives. These policies provide a split of 50% of the death benefit proceeds to the Company and 50% to the officerbs designated beneficiaries

'

'

'

'

'

'

'

'

'

'

'

'

'

Split of death benefit proceeds

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Endorsement_Agreements_Additio

Endorsement Agreements - Additional Information (Details) (USD $)	0 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended			0 Months Ended
	Jul. 15, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Jul. 03, 2014	Sep. 30, 2014
			Advertising and Promotion Expense [Member]	Advertising and Promotion Expense [Member]	Marine MP LLC [Member]	Marine MP LLC [Member]	ETW Corp [Member]	ETW Corp [Member]
Endorsement Agreement Disclosure [Line Items]	'	'	'	'	'	'	'	'
Restricted common stock, shares issued value	'	'	'	'	$8,541,000	'	$5,000,000	'
Prepaid Expense	'	'	'	'	5,171,400	7,300,800	'	4,684,932
Restricted common stock, shares issued	'	'	'	'	'	'	446,853	'
Warrants to purchase common stock	100,000	'	'	'	'	'	'	'
Weighted Average Exercise Price, Balance (in dollars per share)	$11.90	'	'	'	'	'	'	'
Warrants vesting period	'24 months	'	'	'	'	'	'	'
Contractual term of warrants	'5 years	'	'	'	'	'	'	'
Warrant expense	'	'	$69,189	$69,189	'	'	'	'
Fair value of warrants, assumption, expected life (in years)	'	'5 years	'	'	'	'	'	'
Fair value of warrants, assumption, risk free interest rate	'	1.70%	'	'	'	'	'	'
Fair value of warrants, assumption, dividend yield	'	0.00%	'	'	'	'	'	'
Fair value of warrants, assumption, expected volatility	'	55.00%	'	'	'	'	'	'

Biozone_Labs_Acquisition_Addit

Biozone Labs Acquisition - Additional Information (Details) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
		Bldg
Business Acquisition [Line Items]	'	'
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued	'	7,110,730
Stock Issued During Period, Shares, Acquisitions	'	1,200,000
Escrow Period	'	'9 months
Business Acquisition, Share Price	$10	$10
Bargain purchase gain	$5,264,854	$5,264,854
Former Gain Contingency, Recognized in Current Period	1,579,286	1,579,286
Number of Leased Buildings Related to Gain on Settlement	'	1
Seller [Member]	'	'
Business Acquisition [Line Items]	'	'
Stock Issued During Period, Shares, Acquisitions	'	600,000
Escrow [Member]	'	'
Business Acquisition [Line Items]	'	'
Stock Issued During Period, Shares, Acquisitions	'	600,000
BioZone Pharmaceuticals Inc [Member]	'	'
Business Acquisition [Line Items]	'	'
Bargain purchase gain	'	$3,685,568

Biozone_Labs_Acquisition_Sched

Biozone Labs Acquisition - Schedule of Purchase Price Allocation (Details) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Net Tangible Assets	'	'
Current assets	$3,183,152	$3,183,152
Property & equipment	1,859,066	1,859,066
Liabilities assumed	-1,378,920	-1,378,920
Total net tangible assets acquired	3,663,298	3,663,298
Identified Intangible Assets	'	'
Total identified intangible assets acquired	7,133,000	7,133,000
Bargain Purchase Gain	5,264,854	5,264,854
Total	7,110,730	7,110,730
Customer relationships	'	'
Identified Intangible Assets	'	'
Total identified intangible assets acquired	3,130,000	3,130,000
Technology	'	'
Identified Intangible Assets	'	'
Total identified intangible assets acquired	2,158,000	2,158,000
Brand	'	'
Identified Intangible Assets	'	'
Total identified intangible assets acquired	1,776,000	1,776,000
Non-compete agreements	'	'
Identified Intangible Assets	'	'
Total identified intangible assets acquired	69,000	69,000
BioZone Pharmaceuticals Inc [Member]	'	'
Identified Intangible Assets	'	'
Bargain Purchase Gain	'	$3,685,568

Biozone_Labs_Acquisition_Sched1

Biozone Labs Acquisition - Schedule of Business Acquisition, Pro Forma Information (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013		Sep. 30, 2013
Parent Company [Member]	'		'
Business Acquisition [Line Items]	'		'
Total net revenues	$25,343,968		$73,385,193
Net loss	-3,945,836		-13,729,627
Net loss per share - basic and diluted	($0.49)		($2.19)
Weighted average number of common shares used in per share calculations - basic and diluted	8,125,084		6,276,125
BioZone Pharmaceuticals Inc [Member]	'		'
Business Acquisition [Line Items]	'		'
Total net revenues	2,086,985		5,764,116
Net loss	1,625,451		-194,900
Combined Before Pro Forma Adjustments [Member]	'		'
Business Acquisition [Line Items]	'		'
Total net revenues	27,430,953		79,149,309
Net loss	-2,320,385		-13,924,527
Pro Forma Adjustments [Member]	'		'
Business Acquisition [Line Items]	'		'
Net loss	-70,144	[1]	-218,162	[1]
Muscle Pharm Corp. Pro Forma [Member]	'		'
Business Acquisition [Line Items]	'		'
Total net revenues	27,430,953		79,149,309
Net loss	($2,390,529)		($14,142,689)
Net loss per share - basic and diluted	($0.29)		($2.25)
Weighted average number of common shares used in per share calculations - basic and diluted	8,125,084		6,276,125
[1]	Pro forma adjustment to eliminate historical seller depreciation expense and record depreciation and amortization expense resulting from the assets acquired.

Intangible_Assets_Schedule_of_

Intangible Assets - Schedule of Intangible Assets (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Domain name [Member]	Customer relationships	Technology	Non-compete agreements	Patents [Member]	Trademarks [Member]	Brand
Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'
Finite-Lived Intangible Assets, Gross	'	'	'	$3,130,000	$2,158,000	$69,000	$52,501	$35,000	$1,776,000
Finite-Lived Intangible Assets, Accumulated Amortization	-422,102	'	'	-156,500	-202,313	-25,875	-19,596	-17,818	'
Finite-Lived Intangible Assets, Net, Total	6,866,064	'	'	2,973,500	1,955,687	43,125	32,905	17,182	1,776,000
Finite-Lived Intangible Asset, Useful Life	'	'	'	'14 years 3 months 4 days	'7 years 3 months 4 days	'1 year 3 months	'2 years 9 months 7 days	'2 years 3 months	'19 years 3 months 7 days
Indefinite-Lived Intangible Assets (Excluding Goodwill)	'	'	67,665	'	'	'	'	'	'
Intangible Assets, Gross (Excluding Goodwill), Total	7,288,166	'	'	'	'	'	'	'	'
Intangible Assets, Net (Excluding Goodwill), Total	$6,866,064	$155,165	'	'	'	'	'	'	'

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'	'
Amortization of intangible assets	($156,194)	$0	$422,102	$0
Benefit from cumulative adjustment to amortization of intangible assets	$429,790	'	'	'

Intangible_Assets_Schedule_of_1

Intangible Assets - Schedule of Estimated Future Amortization Expense of Intangible Assets (Details) (USD $)	Sep. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
2014 (remaining 3 months)	$222,349
2015	622,061
2016	584,083
2017	571,497
2018	569,491
Thereafter	4,296,583
Finite-Lived Intangible Assets, Net, Total	$6,866,064

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Details) (USD $)	9 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended
	Sep. 30, 2014	Mar. 17, 2014	Dec. 31, 2013	Oct. 02, 2014	Oct. 02, 2014	Oct. 02, 2014	Oct. 02, 2014	Oct. 02, 2014	Oct. 15, 2014
		Restricted Stock	Restricted Stock	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
		Director [Member]	Director [Member]		Restricted Stock	Restricted Stock	Restricted Stock	Restricted Stock	Restricted Stock
					December 31, 2016 [Member]	December 31, 2017 [Member]	December 31, 2018 [Member]	Certain Executives and Other Employees [Member]	Director [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'	'
Stock Repurchased During Period, Shares	100,000	'	'	250,000	'	'	'	'	'
Stock Repurchased During Period, Value	$1,362,881	'	'	$2,500,000	'	'	'	'	'
Stock Issued During Period, Shares, Restricted Stock Award, Gross	'	48,856	19,364	'	'	'	'	1,230,000	4,748
Restricted stock grant vesting percentage	'	'	'	'	60.00%	20.00%	20.00%	'	'